

Local Coverage Determination (LCD): Biomarkers for Oncology (L35396)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	State(s)
Novitas Solutions, Inc.	A and B MAC	04111 - MAC A	J - H	Colorado
Novitas Solutions, Inc.	A and B MAC	04112 - MAC B	J - H	Colorado
Novitas Solutions, Inc.	A and B MAC	04211 - MAC A	J - H	New Mexico
Novitas Solutions, Inc.	A and B MAC	04212 - MAC B	J - H	New Mexico
Novitas Solutions, Inc.	A and B MAC	04311 - MAC A	J - H	Oklahoma
Novitas Solutions, Inc.	A and B MAC	04312 - MAC B	J - H	Oklahoma
Novitas Solutions, Inc.	A and B MAC	04411 - MAC A	J - H	Texas
Novitas Solutions, Inc.	A and B MAC	04412 - MAC B	J - H	Texas
Novitas Solutions, Inc.	A and B MAC	04911 - MAC A	J - H	Colorado New Mexico Oklahoma Texas
Novitas Solutions, Inc.	A and B MAC	07101 - MAC A	J - H	Arkansas
Novitas Solutions, Inc.	A and B MAC	07102 - MAC B	J - H	Arkansas
Novitas Solutions, Inc.	A and B MAC	07201 - MAC A	J - H	Louisiana
Novitas Solutions, Inc.	A and B MAC	07202 - MAC B	J - H	Louisiana
Novitas Solutions, Inc.	A and B MAC	07301 - MAC A	J - H	Mississippi
Novitas Solutions, Inc.	A and B MAC	07302 - MAC B	J - H	Mississippi
Novitas Solutions, Inc.	A and B MAC	12101 - MAC A	J - L	Delaware
Novitas Solutions, Inc.	A and B MAC	12102 - MAC B	J - L	Delaware
Novitas Solutions, Inc.	A and B MAC	12201 - MAC A	J - L	District of Columbia
Novitas Solutions, Inc.	A and B MAC	12202 - MAC B	J - L	District of Columbia
Novitas Solutions, Inc.	A and B MAC	12301 - MAC A	J - L	Maryland
Novitas Solutions, Inc.	A and B MAC	12302 - MAC B	J - L	Maryland
Novitas Solutions, Inc.	A and B MAC	12401 - MAC A	J - L	New Jersey
Novitas Solutions, Inc.	A and B MAC	12402 - MAC B	J - L	New Jersey
Novitas Solutions, Inc.	A and B MAC	12501 - MAC A	J - L	Pennsylvania
Novitas Solutions, Inc.	A and B MAC	12502 - MAC B	J - L	Pennsylvania
Novitas Solutions, Inc.	A and B MAC	12901 - MAC A	J - L	District of Columbia Delaware Maryland New Jersey Pennsylvania

[Back to Top](#)

LCD Information

Document Information

LCD ID
L35396

Original ICD-9 LCD ID
[L34796](#)

Original Effective Date
For services performed on or after 10/01/2015

Revision Effective Date
For services performed on or after 01/01/2018

LCD Title
Biomarkers for Oncology

Revision Ending Date
N/A

Proposed LCD in Comment Period
N/A

Retirement Date
N/A

Source Proposed LCD
N/A

Notice Period Start Date
10/13/2016

Notice Period End Date
11/30/2016

AMA CPT / ADA CDT / AHA NUBC Copyright Statement
CPT only copyright 2002-2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA." Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

CMS National Coverage Policy

This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for biomarkers for oncology services. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD. Neither Medicare payment policy rules nor this LCD replace, modify or supersede applicable state statutes regarding medical practice or other health practice professions acts, definitions and/or scopes of practice. All providers who report services for Medicare payment must fully understand and follow all existing laws, regulations and rules for Medicare payment for biomarkers for oncology services and must properly submit only valid claims for them. Please review and understand them and apply the medical necessity provisions in the policy within the context of the manual rules. Relevant CMS manual instructions and policies may be found in the following Internet-Only Manuals (IOMs) published on the CMS Web site.

IOM Citations:

- CMS IOM Publication 100.02, *Medicare Benefit Policy Manual*, Chapter 15: Section 80.1, 80.1.1, 80.1.2, 80.1.3, Laboratory services must meet applicable requirements of CLIA.
- CMS IOM Publication 100-08, *Medicare Program Integrity Manual*, Chapter 3:
 - Section 3.4.1.3, Diagnosis Code Requirements.
 - Section 3.6.2.3, Limitation of Liability Determinations.

Social Security Act (Title XVIII) Standard References:

- Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.
- Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations.
- Title XVIII of the Social Security Act, Section 1833(e) states that no payment shall be made to any provider for any claim that lacks the necessary information to process the claim.
- Title XVIII of the Social Security Act, Section 1862(a)(1)(D) states that no Medicare payment may be made for any expenses incurred for items or services that are investigational or experimental.

Federal Register References:

- Title 42 Code of Federal Regulations (CFR) section 410.32(d)(3) indicates diagnostic tests are payable only when the physician who is treating the beneficiary for a specific medical problem and who uses the results in such treatment.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Notice: It is not appropriate to bill Medicare for services that are not covered (as described by this entire LCD) as if they are covered. When billing for non-covered services, use the appropriate modifier.

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

The emergence of personalized laboratory medicine has been characterized by a multitude of testing options which can more precisely pinpoint management needs of individual patients. As a result, the growing compendium of products described as biomarkers requires careful evaluation by both clinicians and laboratorians as to what testing configurations are reasonable and necessary under the Medicare Act. There are a plethora of burgeoning tools, including both gene-based (genomic) and protein-based (proteomic) assay formats, in tandem with more conventional (longstanding) flow cytometric, cytogenetic, etc. biomarkers. Classified somewhat differently, there are highly-diverse approaches ranging from single mutation biomarkers to multiple biomarker platforms, the latter of which often depend upon sophisticated biomathematical interpretative algorithms.

The term "biomarker" refers to a broad subcategory of medical signs (i.e., objective indications of medical state observed from outside the patient) which can be measured accurately and reproducibly. Medical signs stand in contrast to medical symptoms, which are limited to indications of health or illness perceived by the patient. In 1998, the National Institute of Health (NIH), defined a biomarker as: "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes pathogenic processes, or pharmacologic response to a therapeutic intervention."

This current LCD focuses upon selected testing in oncology, with some emphasis upon applying the revised 2016 CPT molecular coding format. The LCD primarily applies to molecular biomarker testing, but does involve some other types of related biomarker testing, such as proteomics.

There are separate Local Coverage Determinations (LCDs) that address other biomarkers, which include a multitude of assays which are not specifically discussed below. (Please refer to the Novitas website at www.novitas-solutions.com for a complete listing of LCDs.)

Local Medicare coverage of such biomarkers must be predicated upon four fundamental principles:

1. First, the biomarkers must have proven clinical validity/utility (CVU).
2. Second, to support the medical necessity of the service, there must be acceptance/uptake of specific testing into patient management. **It is essential that physicians be familiar enough with all specific biomarkers, which they order, such that all test results may become clinically actionable.**

3. Third, providers managing oncological conditions must demonstrate that the use of biomarkers will be used to assist in the management/treatment of the beneficiary.
4. Peer-reviewed full manuscript evidence is required to support combination panels for multiple biomarkers, particularly regarding their alleged composite clinical validity/utility. For example; such potential billing for multiple, diverse biomarkers (e.g., diagnostic/monitoring/prognostic/predictive) can only achieve medical necessity when it is clearly evident how each requested biomarker can be individually contributory.

It is useful to categorize oncology biomarkers into functional clusters which reflect both (1) The predominant intent of testing (with the caveat that individual assays may cross over into more than one category) and (2) The relative evidentiary expectations:

1. **Oncology Biomarkers Used for Diagnosis/Classification/Monitoring/Surveillance:** These types of assays are supportable by case-control sensitivity/specificity studies, with appropriate designs in place to minimize the extent of bias and confounding.
2. **Oncology Biomarkers Used for Prognosis/Prediction:** Oncology biomarkers used for prognosis/prediction (i.e., a predictive biomarker is associated with response [benefit] or lack of response to a particular therapy, relative to other available therapy, whereas a prognostic biomarker provides information on the likely outcome of the disease in an untreated individual).

There is a complex and diverse set of study methods which can drive the robust formulation of evidence for such esoteric testing, which are well-summarized by Deverka et al. at the Center for Medical Technology Policy, but there are currently NO standardized thresholds or benchmarks for evaluating the CVU/medical necessity of emerging biomarkers. However, the following sources (although not exhaustive and complete) may help support CVU when requesting reconsideration for coverage of biomarkers that are not included in this LCD:

1. FDA labeling documentation.
2. National Comprehensive Cancer Network (NCCN) Biomarkers Compendium recommendations, particularly where Category 1 evidence is noted.
3. Findings from well-established, independent technology assessments (e.g., Evaluation of Genomic Applications in Practice and Prevention (EGAPP), Agency for Healthcare Research and Quality (AHRQ), Blue Cross and Blue Shield Association Technology Evaluation Center (BCBSA TEC) and the Cochrane Collaboration).
4. Other independent, objective evaluations or systematic literature reviews, which can substantively contribute to the evidence base, including, but not restricted to, emerging National Institutes of Health (National Cancer Institute) guidelines for the accrual of genomics/proteomics clinical validity/utility evidence. Although there is not a prescriptive format for such systematic reviews, the documentation (submitted to Novitas) for reconsideration purposes should include the following three elements:
 - Some type of recurring/periodic Committee structure, which is comprised of at least qualified biomathematicians/methodologists, molecular pathology laboratory specialists and relevant clinicians (e.g., oncologists).
 - Evidence of active sharing of the critical evaluations in a manner that enables sufficiently broad input into this process, and a feasibly wide acceptance of this process by representative molecular pathology stakeholders. There is no preference between such a Committee being based at a single site, or even rotating among several sites.
 - Transparency of the biomarker evaluations via minutes (or a summary of minutes).

Covered Indications

MOLECULAR TESTS

Covered clinical types of application(s) are identified below as diagnostic (DX), prognostic (PROG) or predictive (PRED).

1. Colorectal Cancer
 - KRAS (12/13) - PRED of resistance to an anti-EGFR agent
 - KRAS codon 61 - PRED of resistance to an anti-EGFR agent
 - KRAS codon 146 - PRED of resistance to an anti-EGFR agent
 - NRAS - PRED of resistance to an anti-EGFR agent
 - BRAF - PRED of resistance to an anti-EGFR agent + DX (sporadic vs. Lynch syndrome)
 - PIK3CA - PRED of resistance to an anti-EGFR agent + PROG for local recurrence
 - MSI by PCR - PRED of 5-FU resistance + DX
 - MLH1 promoter hypermethylation - PRED of 5-FU resistance + DX
 - mRNA (oncotype-Colon) – PRED for the recurrence risk for patients with Stage II colon cancer (CPT code 81525)
 - Hereditary colon cancer disorders (CPT codes 81435 and 81436)
 - Sept9 – (CPT code 81327)

2. Non-Small Cell Lung Cancer (NSCLC)
 - EGFR- PRED of anti-EGFR response
 - KRAS (12/13) - PRED of anti-EGFR resistance
 - KRAS codon 61 - PRED of anti-EGFR resistance
 - KRAS codon 146 - PRED of anti-EGFR resistance
 - BRAF - PROG + PRED for anti-RAF inhibitor

3. Melanoma
 - BRAF - PRED of response to Vemurafenib
 - KIT - PRED of response to Imatinib (TKI)
 - NRAS - PROG + PRED for anti-MEK inhibitor

4. Brain
 - BRAF - PRED
 - EGFR - PRED
 - MGMT - PRED
 - IDH1 - DX + PROG
 - IDH2 - DX + PROG
 - PIK3CA - PRED
 - PTEN - PRED
 - CIMP - PRED

5. Thyroid

- BRAF - DX + PRED
- KRAS - PRED for Selumetinib
- HRAS - PRED for Selumetinib
- NRAS - PRED for Selumetinib
- PIK3CA - PRED
- RET - DX
- PAX8/PPARG- DX

ThyraMIR Thyroid miRNA classifier (aPCR based microRNA gene expression classifier) (PRED) evaluates the expression levels of 10miRNA genes within an FNA biopsy: miR-29b-1-5p, miR-31-5p, miR-138-1-3p, miR-139-5p, miR-146b-5p, miR-155, miR-204-5p, miR-222-3p, miR-375, and miR-551b-3p.

CPT code 81545, oncology Thyroid, provides gene expression analysis of 142 genes utilizing fine needle aspirate, algorithm reported as a categorical result.(Afirma - PRED).

ThyraMIR and Afirma services will be considered reasonable and necessary for patients with any of the following conditions:

- An indeterminate pathology on fine needle aspiration
- Patients with one or more thyroid nodules with a history or characteristics suggesting malignancy such as:
 - Nodule growth over time
 - Family history of thyroid cancer
 - Hoarseness, difficulty swallowing or breathing
 - History of exposure to ionizing radiation
 - Hard nodule compared with rest of gland consistency
 - Presence of cervical adenopathy

6. Ovary/Fallopian Tube/Peritoneum

- AKT1 - PRED for PI3K/AKT/mTOR inhibitors
- BRAF - DX + PROG
- KRAS - DX + PROG
- MLH1 promoter hypermethylation - DX
- MSI by PCR - DX
- PIK3CA - PRED for PI3K/AKT/mTOR inhibitors
- PTEN - PRED for PI3K/AKT/mTOR inhibitors
- TP53 - DX + PROG

7. Uterus

- AKT1 - PRED for PI3K/AKT/mTOR inhibitors
- BRAF - PRED
- KRAS - PRED
- MLH1 promoter hypermethylation - DX
- MSI by PCR - DX
- PIK3CA - PRED for PI3K/AKT/mTOR inhibitors
- PTEN - PRED for PI3K/AKT/mTOR inhibitors + DX + PROG
- TP53 - DX + PROG

8. Urinary Tract

- MSI by PCR - DX
- MLH1 promoter hypermethylation - DX

9. Prostate

The PROGENSA® PCA3 Assay (PRED) is an FDA-approved, automated molecular test (assay) that helps physicians determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

- 10. Gastrointestinal Stromal Tumor
 - KIT - PRED for Sumatinib + DX
 - PDGFRA - PRED for Sumatinib + DX

- 11. Cancer of Unknown Primary (CUP)

Molecular testing (via CPT code 81479), using the Rosetta Cancer Origin Test™ (PROG), is considered reasonable and necessary in the pathologic diagnoses of CUP when a conventional surgical pathology/imaging work-up is unable to identify a primary neoplastic site. Other applications of this technology are considered not reasonable and necessary and are considered investigational in the use of diagnosis of specific tumor types such as NSCLC and renal cancers.

TUO CTID (Cancer Type ID) (DX) represented by CPT code 81540 is considered reasonable and necessary in the pathologic diagnoses of CUP when a conventional surgical pathology/imaging work-up is unable to identify a primary neoplastic site. Other applications of this technology are considered not reasonable and necessary and are considered investigational in the use of diagnosis of specific tumor types such as NSCLC and renal cancers.

- 12. Leukemias and Lymphomas
 - Acute lymphoid leukemia (ALL)
 - BCR/ABL1 - DX
 - ABL1 (kinase domain) - PROG
 - IGH - DX
 - TCRB - DX
 - TCRG - DX
 - TP53 - PROG
 - MLL/AF4 - DX
 - E2A/PBX1 - DX
 - ETV6/RUNX1 - DX

 - Acute myeloid leukemia (AML, and including acute promyelocytic leukemia): All PROG, except where noted below.

- PML/RARA - DX
 - RUNX1/RUNX1T1 - DX
 - CBFB/MYH11 - DX
 - FLT3 ITD
 - FLT3 D836
 - NPM1
 - KRAS
 - NRAS
 - KIT
 - CEBPA
 - IDH1
 - IDH2
 - DNMT3A
 - JAK2 (p.V617F)
 - JAK2 (exon 12)
 - MPL
 - DEK/CAN - DX
 - ASXL1
 - EZH2
 - TET2
 - PML/RARalpha (CPT code 81316)
- Hairy cell leukemia
 - IGH somatic hypermutation - PROG
 - IGH - DX
- Aplastic anemia
 - TCRB - DX
 - TCRG - DX
- Burkitt's lymphoma
 - IGH - DX
 - TP53 - PROG
- Myeloproliferative diseases [MPD - essential thrombocytosis (ET), myelofibrosis & polycythemia vera (PV)]
 - BCR/ABL1 - DX
 - JAK2 (p.V617F) - DX
 - JAK2 (exon 12) - DX
 - MPL - DX
 - CALR - DX
 - CSF3R - DX
 - ASXL1 - PROG
 - TET2 - PROG
 - EZH2 - PROG
 - Calr (exon 9) (CPT code 81219)
- Chronic myeloid leukemia (CML) and chronic myelomonocytic leukemia (CMML)

- KRAS - PROG
 - NRAS - PROG
 - BCR/ABL1 - DX
 - ABL1 (kinase domain) - PRED for Imatinib
 - FLT3 ITD - PROG
 - FLT3 D836 - PROG
 - KIT - PROG
 - JAK2 (p.V617F) - PROG
 - JAK2 (exon 12) - PROG
- Chronic lymphoid leukemia (CLL)
 - IGH - DX
 - IGH somatic hypermutation - PROG
 - ATM - PROG
 - TP53 - PROG
 - IGH direct probe method (CPT code 81262)
- Follicular lymphoma
 - DX (CPT code 81479)
- Hypereosinophilia Syndrome (HES)
 - KIT (including p.D816V) - PROG + DX
 - FIP1L1/PDGFRΑ Fusion - DX
- Mantle cell lymphoma
 - CCND1/IGH - DX
- Mastocytosis
 - KIT (including p.D816V) - PROG + DX
 - FIP1L1/PDGFRΑ Fusion - DX
 - TCRG - DX
- T-cell prolymphocytic leukemia
 - TCRB - DX
 - TCRG - DX
- Myelodysplastic syndrome (MDS): All below biomarkers are PROG.

- FLT3 ITD
- FLT3 D836
- NPM1
- KRAS
- NRAS
- KIT
- CEBPA
- IDH1
- IDH2
- DNMT3A
- JAK2 (p.V617F)
- JAK2 (exon 12)
- MPL
- ASXL1
- EZH2
- TET2

- Cytogenomic microarray analysis, or alternatively, a single nucleotide polymorphism (SNP) array for the same testing, is covered for the identification of various mutations. These tests are used in the diagnosis/prognosis of various hematological malignancies.

13. Myeloma Gene Expression Profile (MyPRS) (PROG) isolates plasma cells from myeloma patients, extracts DNA, which is then subjected to MicroArray testing and application of validated software programs to identifying patterns of genetic abnormalities. Seventy highly predictive genes have been identified and correlated to myeloma early relapse. MyPRS gives a predictive risk signature as high-risk or low-risk at this time. A high risk score predicts a less than 20% three-year complete remission where as a low-risk predicts a five-year complete remission of greater than 60%. The predictive value for the stratification of therapeutic interventions allows these patients to be treated in a more personalized manner based on their own genetic profile.

This test is considered reasonable and necessary only after the initial diagnosis of multiple myeloma has been made and will be available to be used in the stratification of therapeutic interventions. It would be inappropriate to use this test as a diagnostic tool or as a monitoring device of ongoing therapy. Other testing is available for this function.

The coverage is set to include only two clinical settings:

- Once after initial diagnosis is made (i.e., please use ICD-10-CM code C90.00). In the event MyPRS was not tested at diagnosis of myeloma and there is ongoing initial therapy with persistent disease, MyPRS can be done still as an initial test.

OR

- If relapse has occurred and a change in the therapeutic modalities is contemplated (i.e., please use ICD-10-CM code C90.02).

Please refer to the Utilization Guidelines section of this policy for frequency limitations.

14. Hereditary neuroendocrine tumor disorders (CPT code 81437) – Must include at least 6 genes with genomic sequence analysis NEX GEN including:

- MAX
- SDHB
- SDHC
- SDHD
- TMEM127
- VHL

Please refer to the Utilization Guidelines section of this policy for frequency limitations.

15. Hereditary neuroendocrine tumor disorders; duplication/deletion analysis panel (CPT code 81438) – must include analysis for:
- SDHB
 - SDHC
 - SDHD
 - VHL
16. Prosigna breast cancer gene signature assay (PROG) (CPT code 81520)

Background

Women with early breast cancer and up to 3 locally positive lymph nodes whose tumor is estrogen-receptor positive will usually receive anti-hormonal therapy such as tamoxifen or aromatase inhibitors. U.S. (NCCN) and international (St. Gallen) guidelines predicate the decision for adjuvant chemotherapy on the size and grade of the breast cancer and other factors including genomic assays that provide additional information on risk of recurrence (Hernandez-Ava et al., 2013). According to a 2014 review, “Prognostic factors provide an indication of whether a patient needs subsequent therapy.” (Paoletti & Hayes, 2014). Similarly, another 2014 review article states, “Efforts should be focused on reducing chemotherapy in patients unlikely to benefit.” (Rampurwala et al., 2014).

The PAM50 breast cancer gene signature test was developed in the late 1990s and initial studies showed a strong correlation with breast cancer recurrence and with complete pathologic response to neoadjuvant chemotherapy (Parker et al., 2009). While test results are reported on a scale of 1-100 as a Risk of Recurrence (ROR) score, the underlying algorithm is also able to classify cases into the luminal A and B, Her2neu, and triple-negative subtype classifications.

The Nanostring nCounter® nucleic acid analysis system replicates the PAM50 algorithm, as an FDA cleared kit, the Prosigna Breast Cancer Gene Signature Assay (FDA, 2013). The Prosigna package insert was most recently updated in January, 2015 (FDA, 2015) reflecting additional studies (Sestak et al., 2014). Notably, the Prosigna platform and the original PAM50 platform have a 0.997 correlation (Dowsett et al., 2013).

For the FDA, the Prosigna test was validated in a large population of post-menopausal, estrogen-receptor positive women based on 1,017 cases of the TransATAC study (Dowsett et al., 2013). The study showed a strong correlation with long-term breast cancer recurrence and added substantial additional prognostic information over a clinical treatment score based on standard clinical variables. This study was replicated in an independent population, also on the Prosigna test, using 1,620 samples from the ABCSG8 trial (Gnant, 2014). A separate analysis of these trials validated prediction of distant recurrence in years 5-10 after initial diagnosis (Sestak et al., 2014) and has been incorporated in the FDA labeling (FDA, 2015). The Prosigna test is issued as separate reports, consistent with FDA review and labeling, for node-negative and node-positive (1-3 node) populations. Analytic performance, precision, reproducibility, and analysis of the clinical validations are provided in the FDA labeling (FDA, 2013; FDA, 2015).

Clinical utility of this breast cancer gene signature has also been assessed. The study of Martin et al. (2015) showed a 20% decision impact on decisions for or against adjuvant chemotherapy in an all-comers population of 200 new cases of incident breast cancer, when Prosigna test information became available after all other clinical information had been considered. The net rates of selecting adjuvant chemotherapy for low, intermediate, and high risk cases was similar to that observed in a meta-analysis of Oncotype DX decision data (Carlson & Roth, 2013). Additional support for the use of these test results in treatment decisions comes from Parker et al. (2009), in which there was a strong association with neoadjuvant chemotherapy response. Low-scoring cases have a very low change of complete pathological response to neoadjuvant chemotherapy, while high-scoring cases approach a 50% chance of complete pathological response. The same findings have been observed for other breast cancer gene signatures based on prognostic algorithms (Chang et al., 2008).

Consistent with the FDA indications for use, this testing will be considered reasonable and necessary only for patients that meet the following criteria:

- Post-menopausal female with **either**
 - ER+, lymph node-negative, stage I or II breast cancer; or
 - ER+, lymph node-positive (1-3 positive nodes), stage II breast cancer.

NON-MOLECULAR ASSAYS

1. The VeriStrat® assay (CPT code 81538) is a mass spectrophotometric, serum-based predictive proteomics assay for NSCLC patients, where "first line" EGFR mutation testing is either wild-type or not able to be tested (e.g., if tissue might not be available). This test is a driver of therapy, most notably EGFR inhibitors such as erlotinib, and it has been validated by randomized controlled studies (Carbone et al. and Stinchcomb et al.) and physician uptake data (Akerley et al.) to support this particular coverage niche.
2. This LCD does not address ALK and ROS1 FISH assays, which are indicated as predictive biomarkers for Crizotinib therapy, since they are currently covered assays. However, it is expected that non-molecular testing for these two biomarkers should provide adequate predictive information.
3. FISH tests for bladder cancer are complex tests based on precision reagents, controls, and mathematical algorithms, all of which must be validated in clinical trials in order to support cutoff points for critical patient care decisions. Therefore, in each local physician's office or laboratory, this category of testing is not easily replicated by miscellaneous research use or ASR reagents. Novitas will consider the coverage of FISH test kits based on peer-reviewed literature and approved manufacturer claims.
4. Although multiple bladder cancer FISH tests may be covered according to the above general criteria, UroVysion™ Bladder Cancer Kit [UroVysion™ Kit] will be considered medically reasonable and necessary only when performed according to the FDA label (Summary of Safety and Effectiveness Data, Food and Drug Administration, January 24, 2005) as follows:

The UroVysion Bladder Cancer Kit [UroVysion™ Kit] is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

5. The OVA1™ proteomic assay (PROG) will be considered reasonable and necessary when performed according to the FDA label using CPT code 81503:
 - OVA1™ identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer. If other test results suggest cancer, referral to an oncologist is appropriate even with a negative OVA1™ result.
 - OVA1™ should be used by primary care physicians or gynecologists as an adjunctive test to complement, not replace, other diagnostic and clinical procedures.
 - OVA1™ uses a blood sample to test for levels of five proteins that change due to ovarian cancer. The test combines the five separate results into a single numerical score between 0 and 10 to indicate the likelihood that the pelvic mass is benign or malignant.

OVA1 has been cleared by the FDA for women who meet all of the following criteria:

- Are over 18 years of age
- Have an ovarian mass
- Have surgery planned

It is not intended for ovarian cancer screening or for a definitive diagnosis of ovarian cancer. Interpreting the test result requires knowledge of whether the woman is pre- or post-menopausal.

6. The Risk of Ovarian Malignancy Algorithm (ROMA™) is a qualitative serum test (PROG) that combines the results of HE4 EIA, ARCHITECT CA 125 II™ and menopausal status into a numerical score. ROMA™ is intended (per FDA clearance) to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy at surgery. ROMA™ will be considered reasonable and necessary for women who meet the following FDA labeling criteria:

- Over age 18;
- Ovarian adnexal mass present for which surgery is planned; and,
- Not yet referred to an oncologist.

ROMA™ must be interpreted in conjunction with an independent clinical and radiological assessment. The test is not intended as a screening or stand-alone diagnostic assay.

Limitations

Note: Please refer to the indications for any restrictions specific to the various assays.

1. Biomarkers not addressed in this LCD or any other Novitas LCD will be considered not reasonable and necessary unless specifically covered by national policy.
2. Most genomic testing should be a once in a lifetime test. Documentation in the medical record should clearly support the need for repeat testing to include the following: recurrence of disease, change in behavior of disease, etc.
3. Non-conventional methods of next generation sequencing (NGS), which can generate much more extensive genomic information than conventional techniques, are currently non-covered. NGS methods which provide more "intermediate" range information (e.g., in the 5-50 mutation range) may be performed in the laboratory, pending adequate quality control, such as CLIA certification, but the actual coding and billing will continue to follow the "one-at-a-time" biomarker approach based on this LCD.
4. Services represented by 0003U, 0005U, 0016U and 0017U are very new tests without clinical utility having been established. These tests are considered investigational and experimental and therefore are non-covered at this time. Services represented by 0002U are considered screening services which are non-covered by Medicare.

For frequency limitations, please refer to the Utilization Guidelines section below.

Notice: This LCD imposes frequency limitations as well as diagnosis limitations that support diagnosis to procedure code automated denials. However, services performed for any given diagnosis must meet all of the indications and limitations stated in this policy, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

As published in CMS IOM 100-08, Chapter 13, Section 13.5.1, in order to be covered under Medicare, a service shall be reasonable and necessary. When appropriate, contractors shall describe the circumstances under which the proposed LCD for the service is considered reasonable and necessary under Section 1862 (a)(1)(A). Contractors shall consider a service to be reasonable and necessary if the contractor determines that the service is:

- Safe and effective.
- Not experimental or investigational (exception: routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000, that meet the requirements of the Clinical Trials NCD are considered reasonable and necessary).
- Appropriate, including the duration and frequency that is considered appropriate for the service, in terms of whether it is:
 - Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member.
 - Furnished in a setting appropriate to the patient's medical needs and condition.
 - Ordered and furnished by qualified personnel.
 - One that meets, but does not exceed, the patient's medical needs.
 - At least as beneficial as an existing and available medically appropriate alternative

The redetermination process may be utilized for consideration of services performed outside of the reasonable and necessary requirements in this LCD.

Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

[Back to Top](#)

Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

- 012x Hospital Inpatient (Medicare Part B only)
- 013x Hospital Outpatient
- 014x Hospital - Laboratory Services Provided to Non-patients
- 018x Hospital - Swing Beds
- 021x Skilled Nursing - Inpatient (Including Medicare Part A)
- 022x Skilled Nursing - Inpatient (Medicare Part B only)
- 023x Skilled Nursing - Outpatient
- 071x Clinic - Rural Health
- 072x Clinic - Hospital Based or Independent Renal Dialysis Center
- 073x Clinic - Freestanding
- 075x Clinic - Comprehensive Outpatient Rehabilitation Facility (CORF)
- 077x Clinic - Federally Qualified Health Center (FQHC)
- 083x Ambulatory Surgery Center
- 085x Critical Access Hospital

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

Note: The contractor has identified the Bill Type and Revenue Codes applicable for use with the CPT/HCPCS codes included in this LCD. Providers are reminded that not all CPT/HCPCS codes listed can be billed with all Bill Type or Revenue Codes listed. CPT/HCPCS codes are required to be billed with specific Bill Type and Revenue Codes. Providers are encouraged to refer to the CMS Internet-Only Manual (IOM) Pub. 100-04, *Medicare Claims Processing Manual*, for further guidance.

- 030X Laboratory - General Classification
- 031X Laboratory Pathology - General Classification

Group 1 Paragraph:

Providers are reminded to refer to the long descriptors of the CPT codes in their CPT book.

Medicare is establishing limited coverage for the following CPT/HCPCS codes, as described in the preceding Coverage Guidance.

Note: Please see the indications and limitations section of the LCD for details regarding CPT codes 81292, 81293, 81294, 81321, 81322, 81323, 81437, 81438, 81479, 81520, 81525, 81540, and 81545.

Please note that the following CPT codes will not have procedure to diagnosis code pairings specified at this time: 81246, 81350, 81400, 81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408, 81435, 81436, and 81503.

Group 1 Codes:

- 81120 Idh1 common variants
- 81121 Idh2 common variants
- 81170 Abl1 gene
- 81175 Asxl1 full gene sequence
- 81176 Asxl1 gene target seq alys
- 81206 Bcr/abl1 gene major bp
- 81207 Bcr/abl1 gene minor bp
- 81208 Bcr/abl1 gene other bp
- 81210 Braf gene
- 81218 Cebpa gene full sequence
- 81219 Calr gene com variants
- 81235 Egfr gene com variants
- 81245 Flt3 gene
- 81246 Flt3 gene analysis
- 81261 Igh gene rearrange amp meth
- 81262 Igh gene rearrang dir probe
- 81263 Igh vari regional mutation
- 81270 Jak2 gene
- 81272 Kit gene targeted seq analys
- 81273 Kit gene analys d816 variant
- 81275 Kras gene variants exon 2
- 81276 Kras gene addl variants
- 81287 Mgmt gene methylation anal
- 81292 Mlh1 gene full seq
- 81293 Mlh1 gene known variants
- 81294 Mlh1 gene dup/delete variant
- 81301 Microsatellite instability
- 81310 Npm1 gene
- 81311 Nras gene variants exon 2&3
- 81313 Pca3/klk3 antigen
- 81314 Pdgfra gene
- 81315 Pml/raralpha com breakpoints
- 81316 Pml/raralpha 1 breakpoint
- 81321 Pten gene full sequence
- 81322 Pten gene known fam variant
- 81323 Pten gene dup/delet variant
- 81327 Sept9 methylation analysis
- 81334 Runx1 gene targeted seq alys
- 81340 Trb@ gene rearrange amplify
- 81342 Trg gene rearrangement anal
- 81350 Ugt1a1 gene
- 81400 Mopath procedure level 1
- 81401 Mopath procedure level 2
- 81402 Mopath procedure level 3

81403 Mopath procedure level 4
 81404 Mopath procedure level 5
 81405 Mopath procedure level 6
 81406 Mopath procedure level 7
 81407 Mopath procedure level 8
 81408 Mopath procedure level 9
 81435 Hereditary colon ca dsordrs
 81436 Hereditary colon ca dsordrs
 81437 Heredtry nurondcrn tum dsrdr
 81438 Heredtry nurondcrn tum dsrdr
 81479 Unlisted molecular pathology
 81503 Onco (ovar) five proteins
 81520 Onc breast mrna 58 genes
 81525 Oncology colon mrna
 81538 Oncology lung
 81540 Oncology tum unknown origin
 81545 Oncology thyroid

Group 2 Paragraph:

The following CPT codes are **non-covered**.

Group 2 Codes:

81450 Targeted genomic seq analys
 0002U Onc clrct 3 ur metab alg plp
 0003U Onc ovar 5 prtn ser alg scor
 0005U Onco prst8 3 gene ur alg
 0009U Onc brst ca erbb2 amp/nonamp
 0013U Onc sld org neo gene reargmt
 0014U Hem hmtlmf neo gene reargmt
 0016U Onc hmtlmf neo rna bcr/abl1
 0017U Onc hmtlmf neo jak2 mut dna

ICD-10 Codes that Support Medical Necessity

Group 1 Paragraph:

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

Medicare is establishing the following limited coverage for the colorectal cancer molecular biomarkers (also including the small intestine) listed below and for MAAA CPT code 81525, mRNA gene expression profiling by real time RT-PCR of 12 genes utilizing ffpe tissue, algorithm and report:

KRAS (12/13) **81275**
 KRAS codon 61 **81276**
 KRAS codon 146 **81276**
 NRAS **81311**
 BRAF **81210**
 PIK3CA **81479**
 MSI by PCR **81301**
 MLH1 promoter hypermethylation **81292, 81293, 81294**
 mRNA **81525**
 Sept9 **81327**

Group 1 Codes:

ICD-10 Codes	Description
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum

ICD-10 Codes	Description
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.1	Malignant neoplasm of anal canal

**Group 2 Paragraph:
Medicare is establishing the following limited coverage for non-small cell lung carcinoma (NSCLC) molecular biomarkers:**

EGFR **81235**
 KRAS (12/13) **81275**
 KRAS codon 61 **81276**
 KRAS codon 146 **81276**
 BRAF **81210**
 Oncology Lung (Veristrat) **81538**

Group 2 Codes:

ICD-10 Codes	Description
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C38.4	Malignant neoplasm of pleura
C45.0	Mesothelioma of pleura

**Group 3 Paragraph:
Medicare is establishing the following limited coverage for melanoma molecular biomarkers:**

BRAF **81210**
 KIT **81272**
 NRAS **81311**

Group 3 Codes:**ICD-10 Codes****Description**

C43.0	Malignant melanoma of lip
C43.10	Malignant melanoma of unspecified eyelid, including canthus
C43.11	Malignant melanoma of right eyelid, including canthus
C43.12	Malignant melanoma of left eyelid, including canthus
C43.20	Malignant melanoma of unspecified ear and external auricular canal
C43.21	Malignant melanoma of right ear and external auricular canal
C43.22	Malignant melanoma of left ear and external auricular canal
C43.30	Malignant melanoma of unspecified part of face
C43.31	Malignant melanoma of nose
C43.39	Malignant melanoma of other parts of face
C43.4	Malignant melanoma of scalp and neck
C43.51	Malignant melanoma of anal skin
C43.52	Malignant melanoma of skin of breast
C43.59	Malignant melanoma of other part of trunk
C43.60	Malignant melanoma of unspecified upper limb, including shoulder
C43.61	Malignant melanoma of right upper limb, including shoulder
C43.62	Malignant melanoma of left upper limb, including shoulder
C43.70	Malignant melanoma of unspecified lower limb, including hip
C43.71	Malignant melanoma of right lower limb, including hip
C43.72	Malignant melanoma of left lower limb, including hip
C43.8	Malignant melanoma of overlapping sites of skin
C43.9	Malignant melanoma of skin, unspecified
D03.0	Melanoma in situ of lip
D03.10	Melanoma in situ of unspecified eyelid, including canthus
D03.11	Melanoma in situ of right eyelid, including canthus
D03.12	Melanoma in situ of left eyelid, including canthus
D03.20	Melanoma in situ of unspecified ear and external auricular canal
D03.21	Melanoma in situ of right ear and external auricular canal
D03.22	Melanoma in situ of left ear and external auricular canal
D03.30	Melanoma in situ of unspecified part of face
D03.39	Melanoma in situ of other parts of face
D03.4	Melanoma in situ of scalp and neck
D03.51	Melanoma in situ of anal skin
D03.52	Melanoma in situ of breast (skin) (soft tissue)
D03.59	Melanoma in situ of other part of trunk
D03.60	Melanoma in situ of unspecified upper limb, including shoulder
D03.61	Melanoma in situ of right upper limb, including shoulder
D03.62	Melanoma in situ of left upper limb, including shoulder
D03.70	Melanoma in situ of unspecified lower limb, including hip
D03.71	Melanoma in situ of right lower limb, including hip
D03.72	Melanoma in situ of left lower limb, including hip
D03.8	Melanoma in situ of other sites
D03.9	Melanoma in situ, unspecified

Group 4 Paragraph:

Medicare is establishing the following limited coverage for brain molecular biomarkers:

BRAF 81210

EGFR 81235

MGMT 81287

PIK3CA 81479

PTEN 81321, 81322, 81323, 81479

CIMP 81479

IDH1 81120

IDH2 81121

Group 4 Codes:

ICD-10 Codes	Description
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe
C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified

Group 5 Paragraph:

Medicare is establishing the following limited coverage for thyroid molecular biomarkers:

BRAF **81210**
 KRAS **81275, 81276**
 NRAS **81311**
 PIK3CA **81479**
 ThyraMIR **81479**
 Afirma **81545**

Group 5 Codes:

ICD-10 Codes	Description
C73*	Malignant neoplasm of thyroid gland
D34	Benign neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland
D44.2*	Neoplasm of uncertain behavior of parathyroid gland
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland
E01.0	Iodine-deficiency related diffuse (endemic) goiter
E01.1	Iodine-deficiency related multinodular (endemic) goiter
E01.2	Iodine-deficiency related (endemic) goiter, unspecified
E04.0	Nontoxic diffuse goiter
E04.1	Nontoxic single thyroid nodule
E04.2	Nontoxic multinodular goiter
E04.8	Other specified nontoxic goiter
E04.9	Nontoxic goiter, unspecified

Group 5 Medical Necessity ICD-10 Codes Asterisk Explanation:

***Note:** C73 and D44.2 should not be reported for ThyraMIR or Afirma.

Group 6 Paragraph:

Medicare is establishing the following limited coverage for uterus/ovary/fallopian tube/peritoneum molecular biomarkers:

AKT1 **81479**
 BRAF **81210**
 KRAS **81275, 81276**
 MLH1 promoter hypermethylation **81292, 81293, 81294**
 MSI by PCR **81301**
 PIK3CA **81479**
 PTEN **81321, 81322, 81323, 81479**

Group 6 Codes:

ICD-10 Codes	Description
C45.1	Mesothelioma of peritoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary
C56.9	Malignant neoplasm of unspecified ovary
C57.00	Malignant neoplasm of unspecified fallopian tube
C57.01	Malignant neoplasm of right fallopian tube
C57.02	Malignant neoplasm of left fallopian tube
C57.10	Malignant neoplasm of unspecified broad ligament
C57.11	Malignant neoplasm of right broad ligament
C57.12	Malignant neoplasm of left broad ligament
C57.20	Malignant neoplasm of unspecified round ligament
C57.21	Malignant neoplasm of right round ligament
C57.22	Malignant neoplasm of left round ligament
C57.3	Malignant neoplasm of parametrium
C57.4	Malignant neoplasm of uterine adnexa, unspecified

Group 7 Paragraph:

Medicare is establishing the following limited coverage for urinary tract molecular biomarkers:

MSI by PCR **81301**

MLH1 promoter hypermethylation **81292, 81293, 81294**

Group 7 Codes:

ICD-10 Codes	Description
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C66.1	Malignant neoplasm of right ureter
C66.2	Malignant neoplasm of left ureter
C66.9	Malignant neoplasm of unspecified ureter
C68.0	Malignant neoplasm of urethra
C68.1	Malignant neoplasm of paraurethral glands
C68.8	Malignant neoplasm of overlapping sites of urinary organs
C68.9	Malignant neoplasm of urinary organ, unspecified

Group 8 Paragraph:

Medicare is establishing the following limited coverage for prostate cancer molecular biomarkers:

PROGENSA® PCA3 Assay **81313**

Group 8 Codes:

ICD-10 Codes	Description
C61	Malignant neoplasm of prostate
D29.1	Benign neoplasm of prostate
D40.0	Neoplasm of uncertain behavior of prostate

ICD-10 Codes	Description
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms
N40.2	Nodular prostate without lower urinary tract symptoms
N40.3	Nodular prostate with lower urinary tract symptoms
N42.31	Prostatic intraepithelial neoplasia
N42.32	Atypical small acinar proliferation of prostate
N42.39	Other dysplasia of prostate
N42.83	Cyst of prostate
R31.1	Benign essential microscopic hematuria
R31.29	Other microscopic hematuria

Group 9 Paragraph:

Medicare is establishing the following limited coverage for gastrointestinal stromal tumor molecular biomarkers:

KIT **81272**
PDGFRA **81314**

Group 9 Codes:

ICD-10 Codes	Description
C49.A0	Gastrointestinal stromal tumor, unspecified site
C49.A1	Gastrointestinal stromal tumor of esophagus
C49.A2	Gastrointestinal stromal tumor of stomach
C49.A3	Gastrointestinal stromal tumor of small intestine
C49.A4	Gastrointestinal stromal tumor of large intestine
C49.A5	Gastrointestinal stromal tumor of rectum
C49.A9	Gastrointestinal stromal tumor of other sites
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system

Group 10 Paragraph:

Medicare is establishing the following limited coverage for acute lymphoid leukemia (ALL) molecular biomarkers:

BCR/ABL1 **81206, 81207, 81208**
ABL1 (kinase domain) **81170**
IGH **81261**
TCRB **81340**
TCRG **81342**
MLL/AF4 **81479**
RUNX1 **81334**

Group 10 Codes:

ICD-10 Codes	Description
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C92.02	Acute myeloblastic leukemia, in relapse

Group 11 Paragraph:

Medicare is establishing the following limited coverage for acute myeloid leukemia (AML, and including acute promyelocytic leukemia) molecular biomarkers:

PML/RARA **81315**
PML/RARalpha **81316**

FLT3 ITD **81245**
 FLT3 D836 **81479**
 NPM1 **81310**
 KRAS **81275, 81276**
 NRAS **81311**
 KIT **81273**
 CEBPA **81218**
 JAK2 (p.V617F) **81270**
 DEK/CAN **81479**
 ASXL1 **81175, 81176**
 EZH2 **81479**
 TET2 **81479**
 IDH1 **81120**
 IDH2 **81121**
 RUNX1 **81334**

Group 11 Codes:

ICD-10 Codes	Description
C92.00	Acute myeloblastic leukemia, not having achieved remission
C92.01	Acute myeloblastic leukemia, in remission
C92.02	Acute myeloblastic leukemia, in relapse
C92.40	Acute promyelocytic leukemia, not having achieved remission
C92.41	Acute promyelocytic leukemia, in remission
C92.42	Acute promyelocytic leukemia, in relapse
C92.50	Acute myelomonocytic leukemia, not having achieved remission
C92.51	Acute myelomonocytic leukemia, in remission
C92.52	Acute myelomonocytic leukemia, in relapse
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse

Group 12 Paragraph:

Medicare is establishing the following limited coverage for hairy cell leukemia molecular biomarkers:

IGH somatic hypermutation **81263**
 IGH **81261**

Group 12 Codes:

ICD-10 Codes	Description
C91.40	Hairy cell leukemia not having achieved remission
C91.41	Hairy cell leukemia, in remission
C91.42	Hairy cell leukemia, in relapse

Group 13 Paragraph:

Medicare is establishing the following limited coverage for aplastic anemia molecular biomarkers:

TCRB **81340**
 TCRG **81342**

Group 13 Codes:

ICD-10 Codes	Description
D60.0	Chronic acquired pure red cell aplasia

ICD-10 Codes	Description
D60.1	Transient acquired pure red cell aplasia
D60.8	Other acquired pure red cell aplasias
D60.9	Acquired pure red cell aplasia, unspecified
D61.01	Constitutional (pure) red blood cell aplasia
D61.09	Other constitutional aplastic anemia
D61.1	Drug-induced aplastic anemia
D61.2	Aplastic anemia due to other external agents
D61.3	Idiopathic aplastic anemia
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes
D61.9	Aplastic anemia, unspecified

Group 14 Paragraph:

Medicare is establishing the following limited coverage for Burkitt's lymphoma molecular biomarkers:

IGH 81261

Group 14 Codes:

ICD-10 Codes	Description
C83.70	Burkitt lymphoma, unspecified site
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck
C83.72	Burkitt lymphoma, intrathoracic lymph nodes
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb
C83.76	Burkitt lymphoma, intrapelvic lymph nodes
C83.77	Burkitt lymphoma, spleen
C83.78	Burkitt lymphoma, lymph nodes of multiple sites
C83.79	Burkitt lymphoma, extranodal and solid organ sites

Group 15 Paragraph:

Medicare is establishing the following limited coverage for myeloproliferative diseases (MPD - essential thrombocytosis [ET], myelofibrosis & polycythemia vera [PV]) molecular biomarkers:

BCR/ABL1 81206, 81207, 81208
JAK2 (p.V617F) 81270
CALR 81479
CALR (exon 9) 81219
CSF3R 81479
ASXL1 81175, 81176
TET2 81479
EZH2 81479

Group 15 Codes:

ICD-10 Codes	Description
D45	Polycythemia vera
D47.1	Chronic myeloproliferative disease
D47.3	Essential (hemorrhagic) thrombocytopenia
D75.81	Myelofibrosis

Group 16 Paragraph:

Medicare is establishing the following limited coverage for chronic myeloid leukemia (CML) and chronic myelomonocytic leukemia (CMML) molecular biomarkers:

KRAS 81275, 81276
NRAS 81311

BCR/ABL1 **81206, 81207, 81208**
ABL1 (kinase domain) **81170**
FLT3 ITD **81245**
FLT3 D836 **81479**
KIT **81273**
JAK2 (p.V617F) **81270**

Group 16 Codes:

ICD-10 Codes	Description
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse

Group 17 Paragraph:

Medicare is establishing the following limited coverage for chronic lymphoid leukemia (CLL) molecular biomarkers:

IGH **81261**
IGH direct probe method **81262**
IGH somatic hypermutation **81263**
ATM **81479**

Group 17 Codes:

ICD-10 Codes	Description
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.11	Chronic lymphocytic leukemia of B-cell type in remission
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse

Group 18 Paragraph:

Medicare is establishing the following limited coverage for follicular lymphoma molecular biomarkers:

IGH/BCL2 **81479**

Group 18 Codes:

ICD-10 Codes	Description
C82.00	Follicular lymphoma grade I, unspecified site
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	Follicular lymphoma grade I, spleen
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites
C82.10	Follicular lymphoma grade II, unspecified site
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	Follicular lymphoma grade II, spleen
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites

ICD-10 Codes**Description**

C82.19	Follicular lymphoma grade II, extranodal and solid organ sites
C82.20	Follicular lymphoma grade III, unspecified, unspecified site
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade III, unspecified, spleen
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
C82.30	Follicular lymphoma grade IIIa, unspecified site
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIIa, spleen
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.40	Follicular lymphoma grade IIIb, unspecified site
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.47	Follicular lymphoma grade IIIb, spleen
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.60	Cutaneous follicle center lymphoma, unspecified site
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
C82.67	Cutaneous follicle center lymphoma, spleen
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites
C82.80	Other types of follicular lymphoma, unspecified site
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
C82.87	Other types of follicular lymphoma, spleen
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites
C82.90	Follicular lymphoma, unspecified, unspecified site
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes

ICD-10 Codes	Description
C82.97	Follicular lymphoma, unspecified, spleen
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites

Group 19 Paragraph:

Medicare is establishing the following limited coverage for Hypereosinophilia Syndrome (HES) molecular biomarkers:

KIT (including p.D816V) **81273**

Group 19 Codes:

ICD-10 Codes Description

D72.1 Eosinophilia

Group 20 Paragraph:

Medicare is establishing the following limited coverage for mastocytosis molecular biomarkers:

KIT (including p.D816V) **81273**

TCRG **81342**

Group 20 Codes:

ICD-10 Codes Description

C96.20 Malignant mast cell neoplasm, unspecified

C96.22 Mast cell sarcoma

C96.29 Other malignant mast cell neoplasm

Group 21 Paragraph:

Medicare is establishing the following limited coverage for T-cell prolymphocytic leukemia molecular biomarkers:

TCRB **81340**

TCRG **81342**

Group 21 Codes:

ICD-10 Codes Description

C95.90 Leukemia, unspecified not having achieved remission

C95.91 Leukemia, unspecified, in remission

C95.92 Leukemia, unspecified, in relapse

Group 22 Paragraph:

Medicare is establishing the following limited coverage for myelodysplastic syndrome (MDS) molecular biomarkers:

FLT3 ITD **81245**

FLT3 D836 **81479**

NPM1 **81310**

KRAS **81275, 81276**

NRAS **81311**

KIT **81273**

CEBPA **81218**

JAK2 (p.V617F) **81270**

ASXL1 **81175, 81176**

EZH2 **81479**
TET2 **81479**
IDH1 **81120**
IDH2 **81121**

Group 22 Codes:

ICD-10 Codes	Description
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.20	Refractory anemia with excess of blasts, unspecified
D46.21	Refractory anemia with excess of blasts 1
D46.22	Refractory anemia with excess of blasts 2
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.4	Refractory anemia, unspecified
D46.Z	Other myelodysplastic syndromes
D46.9	Myelodysplastic syndrome, unspecified

Group 23 Paragraph:

Medicare is establishing the following limited coverage for Myeloma gene expression profile (MyPRS) (CPT code 81479):

Group 23 Codes:

ICD-10 Codes	Description
C90.00*	Multiple myeloma not having achieved remission
C90.02*	Multiple myeloma in relapse

Group 23 Medical Necessity ICD-10 Codes Asterisk Explanation:

***Note: C90.00** should be reported after initial diagnosis has been made and **C90.02** should be reported if there has been a relapse with a change in treatment planned.

Group 24 Paragraph:

Medicare is establishing the following limited coverage for CPT code 81520:

Group 24 Codes:

ICD-10 Codes	Description
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.611	Malignant neoplasm of axillary tail of right female breast

ICD-10 Codes	Description
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast

Group 25 Paragraph:

Medicare is establishing the following limited coverage for CPT codes 81437 and 81438:

Group 25 Codes:

ICD-10 Codes	Description
C7A.010	Malignant carcinoid tumor of the duodenum
C7A.011	Malignant carcinoid tumor of the jejunum
C7A.012	Malignant carcinoid tumor of the ileum
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.020	Malignant carcinoid tumor of the appendix
C7A.021	Malignant carcinoid tumor of the cecum
C7A.022	Malignant carcinoid tumor of the ascending colon
C7A.023	Malignant carcinoid tumor of the transverse colon
C7A.024	Malignant carcinoid tumor of the descending colon
C7A.025	Malignant carcinoid tumor of the sigmoid colon
C7A.026	Malignant carcinoid tumor of the rectum
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion
C7A.090	Malignant carcinoid tumor of the bronchus and lung
C7A.091	Malignant carcinoid tumor of the thymus
C7A.092	Malignant carcinoid tumor of the stomach
C7A.093	Malignant carcinoid tumor of the kidney
C7A.094	Malignant carcinoid tumor of the foregut, unspecified
C7A.095	Malignant carcinoid tumor of the midgut, unspecified
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified
C7A.098	Malignant carcinoid tumors of other sites
C7A.1	Malignant poorly differentiated neuroendocrine tumors
C7A.8	Other malignant neuroendocrine tumors
C7B.01	Secondary carcinoid tumors of distant lymph nodes
C7B.02	Secondary carcinoid tumors of liver
C7B.03	Secondary carcinoid tumors of bone
C7B.04	Secondary carcinoid tumors of peritoneum
C7B.09	Secondary carcinoid tumors of other sites
C7B.1	Secondary Merkel cell carcinoma
C7B.8	Other secondary neuroendocrine tumors
D3A.010	Benign carcinoid tumor of the duodenum
D3A.011	Benign carcinoid tumor of the jejunum
D3A.012	Benign carcinoid tumor of the ileum
D3A.019	Benign carcinoid tumor of the small intestine, unspecified portion
D3A.020	Benign carcinoid tumor of the appendix
D3A.021	Benign carcinoid tumor of the cecum
D3A.022	Benign carcinoid tumor of the ascending colon
D3A.023	Benign carcinoid tumor of the transverse colon
D3A.024	Benign carcinoid tumor of the descending colon
D3A.025	Benign carcinoid tumor of the sigmoid colon
D3A.026	Benign carcinoid tumor of the rectum
D3A.029	Benign carcinoid tumor of the large intestine, unspecified portion
D3A.090	Benign carcinoid tumor of the bronchus and lung
D3A.091	Benign carcinoid tumor of the thymus
D3A.092	Benign carcinoid tumor of the stomach

ICD-10 Codes	Description
D3A.093	Benign carcinoid tumor of the kidney
D3A.094	Benign carcinoid tumor of the foregut, unspecified
D3A.095	Benign carcinoid tumor of the midgut, unspecified
D3A.096	Benign carcinoid tumor of the hindgut, unspecified
D3A.098	Benign carcinoid tumors of other sites
D3A.8	Other benign neuroendocrine tumors

Group 26 Paragraph:

Medicare is establishing the following limited coverage for CPT code 81540 – TUO CTID (Cancer Type ID):

Group 26 Codes:

ICD-10 Codes	Description
C18.1	Malignant neoplasm of appendix
C18.9	Malignant neoplasm of colon, unspecified
C22.0	Liver cell carcinoma
C22.2	Hepatoblastoma
C22.3	Angiosarcoma of liver
C22.4	Other sarcomas of liver
C22.7	Other specified carcinomas of liver
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C25.2	Malignant neoplasm of tail of pancreas
C25.7	Malignant neoplasm of other parts of pancreas
C25.8	Malignant neoplasm of overlapping sites of pancreas
C25.9	Malignant neoplasm of pancreas, unspecified
C33	Malignant neoplasm of trachea
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C43.51	Malignant melanoma of anal skin
C43.52	Malignant melanoma of skin of breast
C43.59	Malignant melanoma of other part of trunk
C45.9	Mesothelioma, unspecified
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48.0	Malignant neoplasm of retroperitoneum
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C56.1	Malignant neoplasm of right ovary

ICD-10 Codes	Description
C56.2	Malignant neoplasm of left ovary
C61	Malignant neoplasm of prostate
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C67.5	Malignant neoplasm of bladder neck
C67.9	Malignant neoplasm of bladder, unspecified
C76.0	Malignant neoplasm of head, face and neck
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis
C79.2	Secondary malignant neoplasm of skin
C79.31	Secondary malignant neoplasm of brain
C79.49	Secondary malignant neoplasm of other parts of nervous system
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C79.61	Secondary malignant neoplasm of right ovary
C79.62	Secondary malignant neoplasm of left ovary
C79.89	Secondary malignant neoplasm of other specified sites
C80.0	Disseminated malignant neoplasm, unspecified
C80.1	Malignant (primary) neoplasm, unspecified
C82.57	Diffuse follicle center lymphoma, spleen
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen
C84.Z7	Other mature T/NK-cell lymphomas, spleen
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen
C85.17	Unspecified B-cell lymphoma, spleen
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.97	Non-Hodgkin lymphoma, unspecified, spleen
C86.1	Hepatosplenic T-cell lymphoma
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts
D01.7	Carcinoma in situ of other specified digestive organs
D01.9	Carcinoma in situ of digestive organ, unspecified
D02.21	Carcinoma in situ of right bronchus and lung
D02.22	Carcinoma in situ of left bronchus and lung
D03.51	Melanoma in situ of anal skin
D03.52	Melanoma in situ of breast (skin) (soft tissue)
D03.59	Melanoma in situ of other part of trunk
D49.0	Neoplasm of unspecified behavior of digestive system
D49.1	Neoplasm of unspecified behavior of respiratory system
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin
D49.3	Neoplasm of unspecified behavior of breast
D49.4	Neoplasm of unspecified behavior of bladder
D49.511	Neoplasm of unspecified behavior of right kidney
D49.512	Neoplasm of unspecified behavior of left kidney
D49.59	Neoplasm of unspecified behavior of other genitourinary organ
D49.6	Neoplasm of unspecified behavior of brain

ICD-10 Codes	Description
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system
D49.89	Neoplasm of unspecified behavior of other specified sites
D49.9	Neoplasm of unspecified behavior of unspecified site
J91.0	Malignant pleural effusion

ICD-10 Codes that DO NOT Support Medical Necessity

Group 1 Paragraph:

All those not listed under the "ICD-10 Codes that Support Medical Necessity" section.

Group 1 Codes: N/A

ICD-10 Additional Information [Back to Top](#)

General Information

Associated Information

Please refer to Local Coverage Article: Biomarkers for Oncology (A52986) for billing information.

Documentation Requirements

1. All documentation must be maintained in the patient's medical record and made available to the contractor upon request.
2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of services(s)). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
3. The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
4. The medical record documentation must support the medical necessity of the services as directed in this policy. Specifically, the medical record should reflect whether any biomarker ordered is diagnostic, prognostic or predictive, as well as be able to clearly correlate any test results with given interventions (e.g., particular selection of chemotherapy).

Utilization Guidelines

In accordance with CMS Ruling 95-1 (V), utilization of these services should be consistent with locally acceptable standards of practice.

The following tests will all be covered once per lifetime per beneficiary:

- CPT code 81437 – Hereditary neuroendocrine tumor disorders
- CPT code 81438 – Hereditary neuroendocrine tumor disorders; duplication/deletion analysis
- ThyraMIR and Afirma tests
 - Should the unlikely situation of a second, unrelated thyroid nodule with indeterminate pathology occur, coverage may be considered upon appeal with supporting documentation
- CPT code 81540 TUO CTID (Cancer TYPE ID)

While some biomarkers have utility for testing once per lifetime, there are some tumor specific scenarios where repeat testing would be needed for assessment of response to therapy or to identify basis of disease progression. In cases with metastatic or recurrent tumors, repeat testing may be useful in determining further clinical management. Also, biomarkers such as BCR-ABL1 fusion, PML-RARA fusion are useful in monitoring response to therapy and predict a response up to four times per annum.

Sources of Information

Contractor is not responsible for the continued availability of websites listed.

Abraham D, Jackson N, Gundara JS, et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. *Clinical Cancer Research*. 2011; 1: 4772-4781.

Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological Analysis of Papillary Thyroid Cancer with PIK3CA Alterations in a Middle Eastern Population. *J Clin Endocrinol Metab*. 2008; 93(2): 611-618.

Akerley WL, Nelson RE, Cowie RH, et al. The Impact of Serum based Proteomic Mass Spectrometry Test on Treatment Recommendations in Advanced Non Small Cell Lung Cancer. *Current Medical Research & Opinion*. 2013; 29(5): 517-25.

Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. *Lancet Oncol*. 2010; 11: 55-65.

Albitar M, Manshouri, Kantarjian H, et al. Correlation between Lower C-MPL Protein Expression and Favorable Cytogenetic Groups in Acute Myeloid Leukemia. *Leukemia Research*. 1999; (23): 63-69.

Alexander EK, Kennedy GC, Zubair WB, et al. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. *New England Journal of Medicine*. 2012; 367: 705-15.

Alexander EK, Schorr M, Kloppner J, et al. Multi-center experience with the Afirma Gene Expression Classifier. *Journal of Clinical Endocrinology Metabolism*. 2014; 99(1): 119-25.

Ali SZ, Cibas ES. *The Bethesda System for Reporting Thyroid Cytopathology. Definitions, criteria and explanatory notes*. New York, Springer. 2010.

Allegra C, Jessup J, Somerfield R, et al. American Society of Clinical Oncology Provisional clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. *Journal of Clinical Oncology*. 2009; 27 (12): 2091-2096.

An HJ, Kim KI, Kim JY, et al. Microsatellite Instability in Endometrioid Type Endometrial Adenocarcinoma is Associated With Poor Prognostic Indicators. *Am J Surg Pathol*. 2007; 31: 846-853.

Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med*. 2004; 350(23): 2343-2351.

Andre T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol*. 2009; 27: 3109-3116.

Asari R, Passler C, Kaczirek K, et al. Hypoparathyroidism After Total Thyroidectomy: A Prospective Study. *Archives of Surgery*. 2008; 143(2): 132-137.

Asnis-Alibozek A, Fine M, Russo P, et al. Cost of Care for Malignant and Benign Renal Masses. *The American Journal of Management Care*. 2013; 19(8): 617-624.

Avet-Loiseau H, Li C, Magrangeas F, et.al. Prognostic significance of copy-number alterations in multiple myeloma. *J. Clin. Oncol*. 2009; 27: 4585-4590.

Bacher U, Kern W, Haferlach C, et al. *Cyclin D1 (CCND1)* Messenger RNA Expression as Assessed by Real-Time PCR contributes to Diagnosis and Follow-up Control in Patients with Mantle Cell Lymphoma. *Experimental Hematology*. 2013; 41(12): 1028-1037.

Bain B. Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1. *Haematologica*. 2010; 95: 696-698.

Bains A, Luthra R, Medeiros L, Zuo Z. FLT3 and NPM1 Mutations in Myelodysplastic Syndromes: Frequency and Potential Value for Predicting Progression to Acute Myeloid Leukemia. *Am J Clin Pathol*. 2011; 135: 62-69.

Ball DW. Medullary Thyroid Cancer: Monitoring and Therapy. *Endocrinology Metabolism Clin North Am*. 2007; 36(3): 823-837.

Balschun K, Haag J, Wenke A K, et al. KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers, Diagnostic and Therapeutic Implications. *The Journal of Molecular*

Diagnostics. 2011; 13 (4): 436-445.

Baro C, Espinet B, Salido M, et al. Cryptic IGH/BCL2 Rearrangements with Variant FISH Patterns in Follicular. *Leukemia Research*. 2011; 35(2): 256-259.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004; 116: 281–297.

Base RC, Hans L, Urban N, et al. Translational Crossroads for Biomarkers. *Clin Cancer Res*. 2005; 11: 6103. doi: 10.1158/1078-0432.CCR-04-2213

Baysan M, Bozdogan S, Cam M, et al. G-Cimp Status Prediction of Glioblastoma Samples Using mRNA Expression Data. *PLOS ONE*. 2012; 7 (11): 1-10.

Beaudenon-Huibregtse S, Alexander EK, Guttler RB, et al. Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid Nodule. *Thyroid*. 2014; 24(10): 1479-1487.

Berruti A, Amoroso V, Gallo F, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: A meta-regression of 29 randomized prospective studies. *Journal of Clinical Oncology*. 2014; 32(34): 3883-3891.

Biekowski M, Piaskowski S, Stoczyska-Fidelus E, et al. Screening for EGFR Amplifications with a Novel Method and their Significance for the Outcome of Glioblastoma Patients. *PLOS ONE*. 2013; 8 (6): 1-10.

Birkeland E, Wik E, Mjos S, et al. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. *British Journal of Cancer*. 2012; 107: 1997-2004.

Bischoff J, Ignatov A, Semczuk A, et al. hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. *Clin Exp Metastasis*. 2012; 29: 889-900.

Bishop JA, Benjamin H, Cholakh H, et al. Accurate Classification of Non-Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach. *Clin Cancer Res*. 2010; 16(2): 610-19.

Blaszyk H, Wang L, Dietmaier W, et al. Upper Tract Urothelial Carcinoma: A Clinicopathologic Study Including Microsatellite Instability Analysis. *Modern Pathology*. 2002; 15(8): 790-797.

Bongiovanni M, Spitale A, Faquin WC, et al. The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis. *Acta Cytologica*. 2012; 56: 333–339.

Bossuyt P, Reitsma J, Linnet, K, et al. Beyond Diagnostic Accuracy: The Clinical Utility of Diagnostic Tests. *Clinical Chemistry*. 2012; 58(12): 1636-1643.

Bouscary D, Preudhomme C, Ribrag V, et al. Prognostic value of c-mpl expression in myelodysplastic syndromes. *Leukemia*. 1995; 9: 783-788.

Bowen D, Frew M, Hills R, et al. RAS Mutation in Acute Myeloid Leukemia is Associated with Distinct Cytogenetic Subgroups but does not Influence Outcome in Patients Younger than 60 Years. *Blood*. 2005; 106 (6): 2113-2119.

Boyd E, Bench A, Goday-Fernandez A, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. *British Journal of Haematology*. 2010; 149: 250-257.

Breen V, Kasabov N, Kamat A, et al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, Urovysion® FISH, NMP22® and cytology based on imputation of multiple datasets. *BMC Medical Research Methodology*. 2015; 15:45 doi:10.1186/s12874-015-0036-8

Broderick D, Di C, Parrett T, et al. Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas. *Cancer Research*. 2004; 64(15): 5048-5050.

Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. *Blood*. 2010; 116(14): 2543-2553.

Brüggemann M, Gökbüget N, Kneba M. Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle. *Seminars in Oncology*. 2012; 39 (1): 47-57.

Brüggemann M, van der Velden VHJ, Raff T, et al. Rearranged T-Cell Receptor Beta Genes Represent Powerful Targets for Quantification of Minimal Residual Disease in Childhood and Adult T-Cell Acute Lymphoblastic

Leukemia. *Leukemia* 2004; 18: 710-719.

Brustugun OT, Khattak AM, Tromborg AK, et al. BRAF-mutations in non-small cell lung cancer. *Lung Cancer*. 2014; 84: 36-38.

Bucheit AD, Syklawer E, Jakob JA, et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. *Cancer*. 2013; 119(21): 3821-9.

Bullinger L, Kronke J, Schon C, et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. *Leukemia*. 2010; 24: 438-449.

Burken MI, Wilson KS, Heller K, et al. The Interface of Medicare Coverage Decision-Making and Emerging Molecular-Based Laboratory Testing. *Genet Med*. 2009; 11(4): 225-31.

Busch K, Keller T, Fuchs U, et al. Identification of Two Distinct MYC Breakpoint Clusters and their Association with Various IGH Breakpoint Regions in the t(8;14) Translocations in Sporadic Burkitt-Lymphoma. *Leukemia*. 2007; 1739-1751.

Cahill S, Smyth P, Denning K, et al. Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. *Molecular Cancer*. 2007; 6:21.

Cahill S, Smyth P, Finn SP, et al. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. *Molecular Cancer*. 2006; 5: 70.

Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression of chronic lymphocytic leukemia. *New England Journal of Medicine*. 2005; 353: 1793-1801.

Campanella N, De Oliveira A, Scapulatempo-Neto C, et al. Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs). *Recent Patents on Anti-Cancer Drug Discovery*. 2013; 8 (3): 288-297.

Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. *J Clin Endocrinol Metab*. 2010; 95(3): 1365-9.

Cappetta M, Perez V, Zubillaga MN, et al. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis. *International Journal of Laboratory Hematology*. 2013; 35: e4-e5.

Carbone DP, Ding K, Roder H, et al. Prognostic and Predictive Role of the Veristat Plasma Test in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. *J Thorac Oncol*. 2012; 7(11): 1653-60.

Care R, Valk P, Goodeve A, et al. Incidence and Prognosis of c-KIT and FLT3 Mutations in Core Binding Factor (CBF) Acute Myeloid Leukaemias. *British Journal of Haematology*. 2003; 121(5): 775-777.

Carlson J, Roth J. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. *Breast Cancer Res and Treat*. 2013; 14(1): 12-22.

Cartwright T, Chao C, Lee M, et al. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer. *Curr Med Res Opin*. 2014; 30(2): 321-328.

Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. *JAMA*. 2011; 305(22): 2327-34.

Catto JWF, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential Expression of hMLH1 and hMSH2 is Related to Bladder Cancer Grade, Stage and Prognosis but Not Microsatellite Instability. *Int J Cancer*. 2003; 105: 484-490.

Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. *American Urological Association Education and Research*. 2016: 1-45.

Chee CE, Meropol NJ. Current status of gene expression profiling to assist decision making in stage II colon cancer. *Oncologist*. 2014; 19(7): 704-711.

- Chen H, Sippel RS, Pacak K. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma & Medullary Thyroid Cancer. *Pancreas*. 2010; 39(6): 775-783.
- Chen W, Huang Q. Detection of FLT3/ITD, JAK2(V617F) and NPM1 Gene Mutations in Chronic Myelomonocytic Leukemia. *Leukemia Research*. 2009; 33(11): E207-E209.
- Chen YT, Kitabayashi N, Zhou XK, et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. *Modern Pathology*. 2008; 21: 1139-1146.
- Chiaretti S, Tavoraro S, Chia E M, et al. Characterization of ABL1 Expression in Adult T-Cell Acute Lymphoblastic Leukemia by Oligonucleotide Array Analysis. *Haematologica/The Hematology Journal* .2007; 92(5): 619-626.
- Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-Biological Features of 5202 Patients with Acute Lymphoblastic Leukemia Enrolled in the Italian AIEOP and GIMEMA Protocols and Stratified in Age Cohorts. *Haematologica*. 2013; 98(11): 1702-1710.
- Chillón M, Santamaría C, García-Sanz R, et al. Long FLT3 Internal Tandem Duplications and Reduced PML-RARa Expression at Diagnosis Characterize a High-Risk Subgroup of Acute Promyelocytic Leukemia Patients. *Haematologica*. 2010; 95: 745-751.
- Chng WJ, Kuehl WM, Bergsage PL, et al. Translocation t(4:14) retains prognostic significance even in the setting of high-risk molecular signature. Letter to the Editor. *Leukemia*. 2007; 22: 459-461.
- Cibas ED, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. *American Journal of Clinical Pathology*. 2009; 132: 658-665.
- Cibas ES, Baloch ZW, Fellegara G, et al. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. *Annals of Internal Medicine*. 2013; 159(5): 325-32.
- Coates A, Winer E, Goldhirsch A, et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Annals of Oncology Advance Access*. 2015; 26(8): 1-38.
- Cobain E, Hayes, D. Indications of Prognostic Gene Expression Profiling in Early Breast Cancer. *Curr. Treat. Options in Oncol*. 2015; 16(23): 1-14.
- Colamaio M, Cali G, Sarnataro D, et al. Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXD5 (Dysadherin) gene. *Journal of Clinical Endocrinology Metabolism*. 2012; 97: E2168–E2178.
- Colamaio M, Borbone E, Russo L, et al. miR 191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. *Journal of Clinical Endocrinology Metabolism*. 2011; 96: E1915–E1924.
- Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2009; 19(11): 1167-1214.
- Corbacioglu A, Scholl C, Schlenk R, et al. Prognostic Impact of Minimal Residual Disease in *CBFB-MYH11*-Positive Acute Myeloid Leukemia. *Journal of Clinical Oncology*. 2010; 28 (23): 3724-3729.
- Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *The Lancet*. 2014; 384: 164-172.
- Curtin J, Busam K, Pinkel D, Bastian B. Somatic Activation of KIT in Distinct Subtypes of Melanoma. *Journal of Clinical Oncology*. 2006; 24(26): 4340-4346.
- Damie R, Wasil T, Fais F, et al. Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. *Blood*. 1999; 94 (6): 1840-1847.
- Daniilidou K, Frangou-Plemenou M, Grammatikakis J, et al. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. *J BUON*. 2013; 18(1): 195-201.
- Daver N, Strati P, Jabbour E, et al. *FLT3* Mutations in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. *American Journal of Hematology*. 2013; 88(1): 56-59.

- Davies L, Welch GH. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. *JAMA*. 2006; 295: 2164-2167.
- Dawson A, Bal S, McTavish B, et al. Inversion and Deletion of 16q22 Defined by Array CGH, FISH and RT-PCR in a Patient with AML. *Cancer Genetics*. 2011; 204(6): 344-347.
- Day F, Jorissen R, Lipton L, et al. PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. *Clinical Cancer Research*. 2013; 19(12): 3285-3296.
- Decaux O, Lode L, Magrangeas F, et al. Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myelome. *Journal of Clinical Oncology*. 2008; 26(24): 4798-4805.
- Dekking E, van der Velden V, Varro R, et al. Flow Cytometric Immunobead Assay for Fast and Easy Detection of PML-RARA Fusion Proteins for the Diagnosis of Acute Promyelocytic Leukemia. *Leukemia*. 2012; 26: 1976-1985.
- Dettmer MS, Perren A, Moch H, et al. MicroRNA profile of poorly differentiated thyroid carcinomas – new diagnostic and prognostic insights. *Thyroid*. 2013; 23(11): 1383-1389.
- De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol*. 2010;11(8): 753-62.
- Devaraj P, Foroni L, Kitra-Roussos V, et al. Detection of BCR-ABL and E2A-PBX1 Fusion Genes by RT-PCR in Acute Lymphoblastic Leukemia with Failed or Normal Cytogenetics. *British Journal of Haematology*. 1995: 349-355.
- Deverka P, Messner D, Dutta T. Center for Medical Technology Policy Effectiveness Guidance Document. Evaluation of Clinical Validity and Clinical Utility of Actionable Molecular Diagnostic Tests in Adult Oncology. Release Date: May 1, 2013.
- Di Narzo AF, Tejpar S, Rossi S, et al. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. *J Natl Cancer Inst*. 2014; 106(10): 1-8.
- Di Nicolantonio F, Martini M, Molinari F, et al. Wild-Type BRAF is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. *Journal of Clinical Oncology* . 2008; 26 (35): 5705-5712.
- Di Noto R, Pardo C, Schiavone EM, et al. Stem Cell Factor Receptor (c-Kit, CD117) is Expressed on Blast Cells from most Immature Types of Acute Myeloid Malignancies but is also a Characteristic of a Subset of Acute Promyelocytic Leukaemia. *British Journal of Haematology*. 1996; 92(3): 562-564.
- Dos Santos LC, da Costa Ribeiro JC, Silva NP, et al. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. *Rev Bras Hematol Hemoter*. 2011; 33(6): 417-24.
- Dos Santos MT, Mitne-Neto M, Miyashiro K, et al. Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. *J Clin Pathol*. 2014; 67: 176-178.
- Dougherty M, Santi M, Brose M, et al. Activating Mutations in *BRAF* Characterize a Spectrum of Pediatric Low-Grade Gliomas. *Neuro-Oncology*. 2010; 12(7): 621-630.
- Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. *Journal of Clinical Oncology*. 2010; 28(11): 1829-1834.
- Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. *J Clin Oncol*. 2013; 31: 2783-2790. doi: 10.1200/JCO.2012.46.1558. Epub 2013 Jul 1.
- Duick DS, Kloppner JP, Diggans JC, et al. Test Results on the Endocrinologist–Patient Decision to Operate on Patients with Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytopathology. *Thyroid*. 2012; 22(10): 996-1001.
- Duployez N, Nibourel O, Marceau-Renaut A, et al. Minimal Residual Disease Monitoring in t(8;21) Acute Myeloid Leukemia Based on *RUNX1-RUNX1T1* Fusion Quantification on Genomic DNA. *American Journal of Hematology*. 2014; 89(6): 1-6.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Report. *Lancet*. 2012; 379: 432-434.

Erickson LA. Papillary Thyroid Carcinoma. *Atlas of Anatomic Pathology*. 2014; 31-50.

Estep AL, Palmer C, McCormick F, Rauen KA. Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy. *PLoS ONE*. 2007; 2(12): e1279.

Fahy K, Augustine L, Sanden M, et al. Clinicians' Real World Perceptions of Pre-Nephrectomy Diagnostic Biopsy Performance as a Driver of Reduction in Unnecessary Surgeries in Renal Tumors. *JKCVHL*. 2015; 2(1): 1-14.

Fang SH, Efron JE, Berho ME, et al. Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. *J Am Coll Surg*. 2014; 219(5): 1056-1069.

Faquin W, Baloch ZW. Fine-Needle Aspiration of Follicular Patterned Lesions of the Thyroid: Diagnosis, Management, and Follow-Up According to National Cancer Institute (NCI) Recommendations. *Diagnostic Cytopathology*. 2010; 38: 731-739.

Fekete M, Santiskulvong C, Eng C, Dorigo O. Effect of PI3K/Akt Pathway Inhibition-Mediated G1 Arrest on Chemosensitization in Ovarian Cancer Cells. *Anticancer Research*. 2012; 32: 445-452.

FDA Labeling for ROMA Assay (Fujirebio R Diagnostics, Inc.)

FDA 510(K) approval document. September 6, 2013

Feng YZ, Shiozawa T, Miyamoto T, et al. BRAF Mutation in Endometrial Carcinoma and Hyperplasia: Correlation with KRAS and p53 Mutations and Mismatch Repair Protein Expression. *Clin Cancer Res*. 2005; 11: 6133-6138.

Filipits M, Nielsen T, Rudas M, et al. The PAM50 Risk of Recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. *Clin Cancer Res*. 2014; 20(5): 1-8.

Fonseca R, Bergasagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma. *Leukemia*. 2009; 23: 2210-2221.

Forconi F, Sozzi E, Cencini E, et al. Hairy Cell Leukemias with Unmutated IGHV Genes Define the Minor Subset Refractory to Single-Agent Cladribine and with more Aggressive Behavior. *Blood*. 2009; 114 (21): 4696-4702.

Franc B, de la Salmoniere P, Lange F, et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. *Human Pathology*. 2003; 34(11): 1092-100.

Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. *Journal of Clinical Endocrinology Metabolism*. 2006; 91: 3411-3417.

Fridman E, Dotan Z, Barshack I, et al. Accurate Molecular Classification Of Renal Tumors Using MicroRNA Expression. *J Mol Diagn*. 2010; 12(5): 687-96.

Gale R, Green C, Allen C, et al. The Impact of *FLT3* Internal Tandem Duplication Mutant Level, Number, Size, and Interaction with *NPM1* Mutations in a Large Cohort of Young Adult Patients with Acute Myeloid Leukemia. *Blood*. 2008; 111 (5): 2776-2784.

Gale R, Hills R, Pizzey A, et al. Relationship between *FLT3* Mutation Status, Biologic Characteristics, and Response to Targeted Therapy in Acute Promyelocytic Leukemia. *Blood*. 2005; 106 (12): 3768-3776.

Gallia G, Rand V, Siu I, et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme. *Mol Cancer Res*. 2006; 4(10): 709-714.

Gao Q, Ye F, Xia X, et al. Correlation between PTEN Expression and PI3K/Akt Signal Pathway in Endometrial Carcinoma. *Med Sci*. 2009; 29(1): 59-63.

Garand R, Beldjord K, Cave H, et al. Flow Cytometry and IG/TCR Quantitative PCR for Minimal Residual Disease Quantitation in Acute Lymphoblastic Leukemia: a French Multicenter Prospective Study on Behalf of the FRALLE, EORTC and GRAALL. *Leukemia*. 2013; 27: 370-376.

Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer. *Cancer Res*. 2005; 65: 10199-10207.

Garcia-Saenz JA, Bermejo B, Estevez, G, et al. SEOM clinical guidelines in early-stage breast cancer 2015. *Clinical Transl Oncol.* 2015; 17(12); 939-945. DOI 10.1007/s12094-015-1427-3.

Garcon I, Libura M, Delabesse E, et al. *DEK-CAN* Molecular Monitoring of Myeloid Malignancies Could Aid Therapeutic Stratification. *Leukemia.* 2005; 19: 1338-1344.

Geisler JP, Goodheart MJ, Sood AK, et al. Mismatch Repair Gene Expression Defects Contribute to Microsatellite Instability in Ovarian Carcinoma. *Cancer.* 2003; 98: 2199-2206.

Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guide lines for Clinical Practice. *Endocrinology Practice.* 2010; 16(Suppl 1): 1-43.

Gifford G, Paul J, Vasey PA, et al. The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients. *Clin Cancer Res.* 2004; 10: 4420-4426.

Giordano TJ, Beaudenon-Huibregtse S, Shinde R, et al. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. *Human Pathology.* 2014; 45(7): 1339-47.

Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. *Oncogene.* 2005; 24: 6646-6656.

Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. *Annals of Oncology.* 2013; 00:1-7.

Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. *Annals of Oncology.* 2013 (Advance Access published December 16, 2013).

Gnant M., Sestak I, Filipits M, et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive early stage breast cancer treated with endocrine therapy: A combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and Intrinsic Subtype. *Annals of Oncology.* Advance Access May 1, 2015.

Goldhirsch A, Winer E, Coates A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus of the Primary Therapy of Early Breast Cancer. *Annals of Oncology.* 2013; 24: 2206-2223.

Gomez Saez JM. Diagnostic and Prognostic Markers in Differentiated Thyroid Cancer. *Current Genomics.* 2011; 12: 597-608.

Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. *Dig Surg.* 2005; 22: 401-414.

Green C, Koo K, Hills R, et al. Prognostic Significance of *CEBPA* Mutations in a Large Cohort of Younger Adult Patients with Acute Myeloid Leukemia: Impact of Double *CEBPA* Mutations and the Interaction with *FLT3* and *NPM1* Mutations. *Journal of Clinical Oncology.* 2010; 28 (16): 2739-2747.

Gruber JJ, Colevas AD. Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients. *Oncologist.* 2015; 20(2): 113-126. Epub 2015 Jan 23.

Guikema J, deBoer C, Haralambieva E, et al. IGH Switch Breakpoints in Burkitt Lymphoma: Exclusive Involvement of Noncanonical Class Switch Recombination. *Genes, Chromosomes & Cancer.* 2006; 45(9): 808-819.

Gunn S. Mohammed MS, Gorre ME, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. *J. Mol. Diagn.* 2008; 10:442-451.

Haessler J, Shaughnessy JD, Zhan F, et al. Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. *Clin Cancer Res.* 2007; 13(23): 7073-7079.

Haferlach C, Bacher U, Haferlach T, et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the *RUNX1*, *KRAS* and *NRAS* and *NF1* genes and mediates adverse prognosis both in MDS and in

AML: a study in 39 cases of MDS or AML. *Leukemia*. 2011; 25: 874-877.

Hamaguchi H, Nagata K, Yamamoto K, et al. Establishment of a Novel Human Myeloid Leukaemia Cell Line (FKH-1) with T(6;9) (p23;q34) and the Expression of *dek-can* Chimaeric Transcript. *British Journal of Haematology*. 1998; 102(5): 1249-1256.

Han C, Ma J, Zhao J, et al. EGFR Mutations, Gene Amplification, and Protein Expression and KRAS Mutations in Primary and Metastatic Tumors of Nonsmall Cell Lung Cancers and Their Clinical Implications: A Meta-Analysis. *Cancer Investigation*. 2011; 29: 626-634.

Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. *British Journal of Cancer*. 2010; 102: 1219-1223.

Hari PN, Zhang MJ, Roy V, et al. Is the international Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. *Leukemia*. 2009; 23(8): 1528-34. Doi: 10.1038/leu.2009.61

Hayette S, Tigaud I, Thomas X, et al. Identification of a Rare e6a2 BCR-ABL Fusion Gene During the Disease progression of Chronic Myelomonocytic Leukemia: A Case Report. *Leukemia*. 2004; 18: 1735-1736.

He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. *Proceedings of the National Academy of Science*. 2005; 102: 19075-19080.

He M, Breese V, Hang S, Zhang C, Xiong J, Jackson C. BRAF V600E Mutations in Endometrial Adenocarcinoma. *Diagn Mol Pathol*. 2013; 22(1): 35-40.

He Y, Van't Veer LJ, Mikolajewska-Hanclich I, et al. PIK3CA mutations predict local recurrences in rectal cancer patients. *Clin Cancer Res*. 2009; 15(22): 6956-62.

Hegedus L. Clinical practice. The thyroid nodule. *New England Journal of Medicine*. 2004; 351: 1764-1771.

Helmle KE, Otto CJ, Constantinescu G, Honore LH, Andrew SE. Variable MLH1 promoter methylation patterns in endometrial carcinomas of endometrioid subtype lacking DNA mismatch repair. *Int J Gynecol Cancer*. 2005; 15: 1089-1096.

Herandez-Aya L, Gonzalez-Angulo A. Adjuvant Systemic Therapies in Breast Cancer. *Surg Clin North Am*. 2013; 93(2): 473-491.

Herling M, Patel K, Teitell M, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. *Blood*. 2008; 111: 328-337.

Hershman J, Lyko A. Follicular Thyroid Carcinoma. *Endocrine Updates*. 2012; 32: 155-169.

Holmfeldt L, Wei L, Diaz-Flores E, et al. The Genomic Landscape of Hypodiploid Acute Lymphoblastic Leukemia. *Nature Genetics*. 2013; 45(3): 242-252.

Horny H, Lange K, Sotlar K, et al. Increase of Bone Marrow Lymphocytes in Systemic Mastocytosis: Reactive Lymphocytosis or Malignant Lymphoma? Immunohistochemical and Molecular Findings on Routinely Processed bone Marrow Biopsy Specimens. *J Clin Pathol*. 2003; 56: 575-578.

Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. *Haematologica*. Sept 2010.

Hou H, Kuo Y, Liu C, et al. *DNMT3A* Mutations in Acute Myeloid Leukemia: Stability during Disease Evolution and Clinical Implications. *Blood*. 2012; 119(2): 559-568.

Hughes T, Branford S. Molecular Monitoring of BCR-ABL as a Guide to Clinical Management in Chronic Myeloid Leukaemia. *Blood Rev*. 2006; 20 (1): 29-41.

Hummel J, Carmen Frias Kletecka M, Sanks J, et al. Concomitant *BCR-ABL1* Translocation and *JAK2V617F* Mutation in Three Patients with Myeloproliferative Neoplasms. *Diagn Mol Pathol*. 2012; 21: 176-183.

Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. *Cancer*. 2000; 89(1): 202-17.

Ida C, Lambert S, Fausto J, et al. BRAF Alterations are Frequent in Cerebellar Low-Grade Astrocytomas with Diffuse Growth Pattern. *J Neuropathol Exp Neurol*. 2012; 71(7): 631-639.

Ikezo T, Kojima S, Furihata M, et al. Expression of p-JAK2 Predicts Clinical Outcome and is a Potential Molecular Target of Acute Myelogenous Leukemia. *International Journal of Cancer*. 2011; 129(10): 2512-2521.

Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. *Cancer Research*. 2005; 65: 7065-7070.

Itonaga H, Tsushima H, Imanishi D, et al. Molecular Analysis of the BCR-ABL1 Kinase Domain in Chronic-Phase Chronic Myelogenous Leukemia Treated with Tyrosine Kinase Inhibitors in Practice: Study by the Nagasaki CML Study Group. *Leukemia Research*. 2014;38 (1): 76-83.

Jain P, Kantarjian H, Patel K, et al. Mutated *NPM1* in Patients with Acute Myeloid Leukemia in Remission and Relapse. *Leukemia & Lymphoma* 2013: 1-8.

Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. *Cancer*. 2012; 118(16): 4014-23.

Jeuken J, Sijben A, Alenda C, et al. Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics. *Brain Pathology*. 2009; 19: 661-671.

Jiang Y, Gao B, Zhang X, et al. Prevention and treatment of recurrent laryngeal nerve injury in thyroid surgery. *International Journal of Clinical Experience in Medicine*. 2014; 7(1): 101-7.

Jo VY, Stelow EB, Dustin SM, et al. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda system for reporting thyroid cytopathology. *American Journal of Clinical Pathology*. 2010; 134: 450-6.

Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. *Journal of Immunotherapy*. 2012; 35: 66-72.

Kadia T, Kantarjian H, Kornblau S, et al. Clinical and Proteomic Characterization of Acute Myeloid Leukemia with Mutated RAS. *Cancer*. 2012; 118(22): 5550-5559.

Kaeferstein A, Krug U, Tiesmeier J, et al. The emergence of a C/EBP α mutation in the clonal evolution of MDS towards secondary AML. *Leukemia*. 2003; 17: 343-349.

Kaneki E, Oda Y, Ohishi Y, et al. Frequent Microsatellite Instability in Synchronous Ovarian and Endometrial Adenocarcinoma and Its Usefulness for Differential Diagnosis. *Human Pathology*. 2004; 35: 1484-1493.

Kavalieris L, O'Sullivan P, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. *The Journal of Urology*. (2017), DOI 10.1016/j.juro.2016.12.010

Kavalieris L, O'Sullivan PJ, Suttie JM, et al. A segregation index combining phenotypic (clinical Characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. *BMC Urology*. 2015; 15: 23. DOI 10.1186/s12894-015-0018-5

Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. *J Clin Oncol*. 2011; 29: 2121-2127.

Kelemen K, Kovacsovics T, Braziel R, et al. RAS Mutations in Therapy-Related Acute Myeloid Leukemia after Successful Treatment of Acute Promyelocytic Leukemia. *Leukemia & Lymphoma*. 2012; 53(5): 999-1002.

Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. *J Clin Oncol*. 2011; 29(35): 4620-4626.

Keutgen XM, Filicori F, Crowley MJ, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. *Clinical Cancer Research*. 2012; 18:2032-2038.

Kilon A, Noel P, Akin C, et al. Elevated Serum Tryptase Levels Identify a Subset of Patients with a Myeloproliferative Variant of Idiopathic Hypereosinophilic Syndrome Associated with Tissue Fibrosis, Poor Prognosis, and Imatinib Responsiveness. *Blood*. 2003; 101(12): 4660-4666.

Kim I, Kim H, Choung H, et al. PML/RARA Rearrangement Associated with a t(15;19;17) in a Case of Acute Myeloid Leukemia with Abundant Myelocytes with Salmon-pink Cytoplasm. *Cancer Genetics and Cytogenetics*. 2006; 169(1): 81-82.

Kim TH, Park YJ, Lim JA, et al. The Association of the BRAFV600E Mutation With Prognostic Factors and Poor Clinical Outcome in Papillary Thyroid Cancer: A Meta-Analysis. *Cancer*. 2012; 118: 1764-73.

Kitano M, Rahbari R, Patterson EE, et al. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. *Thyroid*. 2012; 22: 285-291.

Kiyoi H, Naoe T, Nakano Y, et al. Prognostic Implication of FLT3 and N-RAS Gene Mutations in Acute Myeloid Leukemia. *Blood*. 1999; 93(9): 3074-3080.

Kohlmann A, Grossmann V, Klein H, et al. Next-Generation Sequencing Technology Reveals a Characteristic pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in *TET2*, *CBL*, *RAS*, and *RUNX1*. *Journal of Clinical Oncology*. 2010; 28 (24): 3858-3865.

Kolasa IK, Rembiszewska A, Janiec-Jankowska A, et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to *TP53*, *K-RAS* and *BRCA1* mutations. *Gynecologic Oncology*. 2006; 103: 692-697.

Kolquist K, Schultz RA, Furrow A, et al. Microarray-based comparative genomic hybridization of cancer targets reveals novel recurrent genetic aberrations in the myelodysplastic syndromes. *Cancer Genet*. 2011; 204: 603-628.

Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. *Nature Reviews Cancer*. 2006; 6(4): 292-306.

Kook H, Risitano An, Zeng W, et al. Changes in T-cell Receptor VB Repertoire in Aplastic Anemia: Effects of Different Immunosuppressive Regimens. *Blood*. 2002; 99 (10): 3668-3675.

Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. *Leukemia*. 2010; 24: 1094-1096.

Krakstad C, Birkeland E, Seidel D, et al. High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated. *PLoS ONE*. 2012; 7(12): e52795.

Kristensen T, Vestergaard H, Bindslev-Jensen C, et al. Sensitive KIT D816V Mutation Analysis of Blood as a Diagnostic Test in Mastocytosis. *American Journal of Hematology*. 2014: 1-6.

Labourier E, Shifrin A, Busseniers AE, et al. Molecular testing for miRNA, mRNA and DNA on fine needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. *Journal of Clinical Endocrinology and Metabolism*. 2015; 100(7): 2743-2750. Doi:10.1210/jc.2015-1158

Lai A, Kharbanda S, Pope W, et al. Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma from a Distinct Cell of Origin. *Journal of Clinical Oncology*. 2011; 29 (34): 4482-4490.

Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. *J Clin Oncol*. 2007; 25(16): 2205-2211.

Lazaris AC, Zarogiannos A, Kavantzias N, et al. MLH1 Mismatch Repair Gene Product is Associated with Apoptotic Potential of Urothelial Bladder Carcinomas. *Anticancer Research*. 2006; 26: 1535-1542.

Lee L, How J, Tabah RJ, et al. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. *Journal of Clinical Endocrinology and Metabolism*. 2014; 99(8): 2674-82.

Leventaki V, Rodic V, Tripp S, et al. TP53 Pathway Analysis in Paediatric Burkitt Lymphoma Reveals Increased MDM4 Expression as the only TP53 Pathway Abnormality Detected in a Subset of Cases. *British Journal of Haematology*. 2012; 158(6): 763-771.

Levine RI, Gilliland DG. JAK-2 Mutations and their Relevance to Myeloproliferative Disease. *Curr Opin Hematol*. 2007; 14(1): 43-7.

Ley T, Ding L, Walter M, et al. DNMT3A Mutations in Acute Myeloid Leukemia. *The New England Journal of Medicine*. 2010; 363(25): 2424-2433.

- Li B, Liu S, Niu Y, et al. Altered Expression of the TCR Signaling Related Genes CD3 and FC γ RI γ in Patients with Aplastic Anemia. *Journal of Hematology & Oncology*. 2012; 5: 1-7.
- Li H, Robinson KA, Anton B, et al. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. *Journal of Clinical Endocrinology and Metabolism*. 2011; 96(11): E1719-26.
- Liao X, Morikawa T, Lochhead P, et al. Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review. *Clinical Cancer Research*. 2012; 18(8): 2257-2268.
- Lin C, Lai Y, Lin T, et al. Clinicopathologic Features and Prognostic Analysis of MSI-High Colon Cancer. *Int J Colorectal Dis*. 2012; 27(3): 277-286.
- Lin J, Yao D-m, Qian J, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. *Ann Hematol*. 2012; 91: 519-525.
- Lin J, Yao D-m, Qian J, et al. Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *PLoS ONE*. 2011; 6(10): e26906.
- Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Arch Pathol Lab Med*. 2013; 137(6): 828-60.
- Liu L, Wang J, Li X, et al. miR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma. *Biochemistry Biosphysics Research Community*. 2015; 457(4): 621-6.
- Liu W, X Tan, Luo X, et al. Prognostic Significance of Tet Methylcytosine Dioxygenase 2 (TET2) Gene Mutations in Adult Patients with Acute Myeloid Leukemia: a Meta-analysis. *Leukemia & Lymphoma*. 2014; 55: 1-8.
- Liu Y, Yanbin S, Wenli M, et al. Decreased MicroRNA-30a Levels are Associated with Enhanced *ABL1* and *BCR-ABL1* Expression in Chronic Myeloid Leukemia. *Leukemia Research*. 2013; 37(3): 349-356.
- Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. *American Journal of Surgical Pathology*. 2004; 28(10):1336-40.
- Lorenzo F, Nishii K, Monma F, et al. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. *Leukemia Research*. 2006; 30: 1235-1239.
- Lotan Y, O'Sullivan P, Raman JD, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*. 2017; <http://dx.doi.org/10.1016/j.urolonc.2017.03.008>
- Lu J, Getz G, Miska EA. MicroRNA expression profiles classify human cancers. *Nature*. 2005; 435: 834-838.
- Lubitz CC, Kong CY, McMahon PM, et al. Annual Financial Impact of Well-Differentiated Thyroid Cancer Care in the United States. *Cancer*. 2014; 120: 1345-52.
- Lundin C, Hjorth L, Behrendtz M, et al. Submicroscopic Genomic Imbalances in Burkitt Lymphomas/Leukemias: Association with Age and Further Evidence that 8q24/MYC Translocations are not Sufficient for Leukemogenesis. *Genes, Chromosomes & Cancer*. 2013; 52: 370-377.
- Mackay HJ, Gallinger S, Tsao MS, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). *European Journal of Cancer*. 2010; 46: 1365-1373.
- Marcucci G, Maharry K, Wu Y, et al. *IDH1* and *IDH2* Gene Mutations Identify Novel Molecular Subsets within De Novo Cytogenetically Normal Acute Myeloid Leukemia: a Cancer and Leukemia Group B Study. *Journal of Clinical Oncology*. 2010; 28 (14): 2348-2355.
- Martin M, Gonzalez-Rivera M, Morales S, et al. Prospective study of the impact of Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. *Current Medical Research & Opinion*. 2015; 1-9.
- Mazzaferri EL, de los Santos ET, Rofagha-Keyhani S. Solitary thyroid nodule: diagnosis and management. *Medical Clinics of North America*. 1988; 72: 1177-1211.

McHenry CR, Slusarczyk SJ. Hypothyroidism following hemithyroidectomy: Incidence, risk factors, and management. *Surgery*. 2000; 128:994-8.

McIver B, Castro MR, Morris JC, et al. An Independent Study of a Gene Expression Classifier (Afirma) in the Evaluation of Cytologically Indeterminate Thyroid Nodules. *Journal of Clinical Endocrinology and Metabolism*. 2014; 99: 4069-4077.

Mehta V, Nikiforov YE, Ferris RL. Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. *Head & Neck*. 2013; 35(10):1499-506.

Metzeler K, Maharry K, Radmacher M, et al. *TET2* Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. *Journal of Clinical Oncology*. 2011; 29(10): 1373-1380.

Mian C, Pennelli G, Fassan M, et al. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. *Thyroid*. 2012; 22: 890-896.

Michael MZ, O' Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. *Molecular Cancer Research*. 2003; 1:882 - 891.

Mikami T, Nemoto Y, Numata Y, et al. Small Gastrointestinal Stromal Tumor in the Stomach: Identification of Precursor for Clinical Gastrointestinal Stromal Tumor Using C-KIT and A-Smooth Muscle Actin Expression. *Human Pathology*. 2013; 44(12): 2628-2635.

Mitomo S, Maesawa C, Ogasawara S, et al. Downregulation of miR 138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. *Cancer Science*. 2008; 99: 280-286.

Myers MB, McKim KL, Parsons BL. A Subset of Papillary Thyroid Carcinomas Contain KRAS Mutant Subpopulations at Levels Above Normal Thyroid. *Molecular Carcinogenesis*. 2014; 53: 159-167.

Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment. *Journal of Oncology*. 2011. Article ID 542358, 13 pages, 2011.

Nair B, Shaughnessy Jr JD, Zhou Y, et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. *Blood*. 2009; 113: 6572-6575.

National Cancer Institute. SEER Stat Fact Sheets: Thyroid Cancer. Bethesda, MD. Available at: <http://seer.cancer.gov/statfacts/html/thyro.html>. Published April 2014. Accessed on February 12, 2015

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 2. 2016.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Thyroid Carcinoma. Version 1.2013.

National Comprehensive Cancer Network (NCCN). Non-Hodgkin's Lymphoma (NHL) (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Page CSLL-1, CSLL-A). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Chronic Myelogenous Leukemia (CML) (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf (Page CML-1, CML-2, CML-3, CML-4, CML-5, CML-A, CML-6, CML-8). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Chronic Myelogenous Leukemia (CML) (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf (Page CML-J, CML-2, CML-3, CML-4, CML-5, CML-A, CML-6). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Non-Hodgkin's Lymphoma (NHL) (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Page FOLL-1). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Non-Hodgkin's Lymphoma (NHL) (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Page HCL-1). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Non-Hodgkin's Lymphoma (NHL) (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Page MANT-1). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Acute Myeloid Leukemia (AML) (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (Page AML-A). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Acute Myeloid Leukemia (AML) (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (Page AML-1, AML-10, AML-A). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Acute Lymphoblastic Leukemia (Version 3.2013). http://www.nccn.org/professionals/physician_gls/pdf/all.pdf (Page ALL-1). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Acute Lymphoblastic Leukemia (Version 3.2013). http://www.nccn.org/professionals/physician_gls/pdf/all.pdf (Page ALL-D 3 of 4, ALL-7). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Acute Myeloid Leukemia (AML) (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (Page AML-2, AML-A, AML-5, AML-6). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers (Version 1.2014). http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. (Page GLIO-3). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers (Version 1.2014). http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. (Page ASTR-1). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers (Version 1.2014). http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. (Page ASTR-1). Accessed April 25, 2014.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer (Version 2.2014). Accessed 12/12/2013. NCCN.org

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer (Version 2.2014). Accessed 12/12/2013. NCCN.org

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma (Version 2.2014). Accessed 12/12/2013. NCCN.org

National Comprehensive Cancer Network (NCCN). Colon Cancer (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (Page COL-A 4 of 5, COL-5, COL-9). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Colon Cancer (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (Page COL-A 4 of 5, COL-3, COL-4, COL-6, COL-7, COL-D). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Melanoma (Version 4.2014). http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. (Page ME-E 1 of 4). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Non-Small Cell Lung Cancer (NSCLC) (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. (Page NSCL-A 3 of 4, NSCL-16, NSCL-H). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Non-Small Cell Lung Cancer (NSCLC) (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. (Page NSCL-A 3 of 4). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in colon cancer 2015 v2.0. Available at: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

National Comprehensive Cancer Network (NCCN). Myelodysplastic Syndromes (MDS) (Version 2.2014). https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. (Page MDS-2). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Soft Tissue Sarcoma (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf (Page GIST-1, GIST-B, SARCB 3 of 3). Accessed April 25, 2014.

National Comprehensive Cancer Network (NCCN). Thyroid Carcinoma (Version 4.2014). http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. (Page MEDU-1, MEDU-2). Accessed April 25,

2014.

Ng KL, Rajandram R, Morais C, et al. Differentiation of Oncocytoma From Chromophobe Renal Cell Carcinoma (RCC). *J Clin Pathol*. 2014;67(2): 97-104.

Nguyen G-K, Lee MW, Ginsberg J, et al. Fine-needle aspiration of the thyroid: an overview. *CytoJournal*. 2005; 2:12.

Niedzwiecki D FW, Venook AP, et al. Association between ColDx assay result and recurrence-free interval in Stage II colon cancer patients on CALGB (Alliance) 9581. ASCO-GI Annual Meeting January 16-18. 2014. Abst#455.

Nielsen C, Birgens H, Nordestgaard B, Bojesen S. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. *British Journal of Haematology*. 2012; 160: 70-79.

Nielsen TO, Parker JS, Leung S, et al. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer. *Clin Cancer Res*. 2010; 16: 5222.

Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. *BMC Cancer*. 2014; 14: 177.

NIH/NCI draft guidelines presented on a poster at the Markers in Cancer meeting on October 11, 2012. Citation: *J Clin Oncol*. 2012 (suppl 30; abstr 58).

Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. *Journal of Clinical Endocrinology and Metabolism*. 2008; 93, 1600–1608.

Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *J Clin Endocrinol Metab*. 2011; 96(11): 3390-7.

Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules *Journal of Clinical Endocrinology and Metabolism*. 2009; 94: 2092–2098.

Nodin B, Zendeherokh N, Sundstrom M, Jirstrom K. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. *Diagnostic Pathology*. 2013; 8: 106.

Nout RA, Bosse T, Creutzberg CL, et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/ β -catenin and P53 pathway activation. *Gynecologic Oncology*. 2012; 126: 466-473.

O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. *J Clin Oncol*. 2011; 29(25): 3381-3388.

Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of Molecular Testing to Thyroid Fine-Needle Aspiration Cytology of "Follicular Lesion of Undetermined Significance/Atypia of Undetermined Significance." *Cancer Cytopathology*. 2010; 118:17–23.

Oien KA and Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. *Annals of Oncology*. 2012; 23(10): 271-277. doi: 10.1093/annonc/mds357

Olson R, Brastianos P, Palma D. Prognostic and Predictive Value of Epigenetic Silencing of MGMT in Patients with High Grade Gliomas: a Systematic Review and Meta-Analysis. *J Neurooncol*. 2011;105(2): 325-335.

Oscier DG. Cytogenetic and Molecular Abnormalities in Chronic Lymphocytic Leukaemia. *Blood Reviews*. 1994; 8(2): 88-96.

O'Sullivan P, Sharples K, Dalphin M, et. al. A Multigene Urine Test for the Detection and Stratification of Bladder Cancer in Patients Presenting with Hematuria. *The Journal of Urology*. 2012; 188: 741-747.

Pallante P, Battista S, Pierantoni GM, et al. Deregulation of microRNA expression in thyroid neoplasias. *Nature Reviews of Endocrinology*. 2014; 10: 88-101.

Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. *Endocrine*

Related Cancer. 2006; 13: 497–508.

Pandor A, Eggington S, Paisley S, et al. The clinical and cost effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. *Health Technol Assess*. 2006; 10(41).

Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol*. 2011; 29(15): 2046-51.

Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *The New England Journal of Medicine*. 2004; 351(27): 2817-2826.

Paik S, Tang G, Shak S, et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer, *J Clin Oncol*. 2006; 24(23): 3726-3734.

Pálóczi K, Poros A, Szelenyi J, et al. TCR Gamma/Delta Bearing Lymphocytes in Peripheral Blood of Allogenic Bone Marrow Transplanted Patients. *Leukemia*. 1992; 6:(Suppl. 3).

Palumbo A and Anderson K. Multiple Myeloma. *NEJM*. 2011; 364:1046-1060. Doi: 10.1056/NEJMra1011442

Papaemmanuil E, Rapado I, Li Y, et al. RAG- Mediated Recombination is the Predominant Driver of Oncogenic Rearrangement in *ETV6-RUNX1* Acute Lymphoblastic Leukemia. *Nature Genetics*. 2014; 46 (2): 116-125.

Pardanani A, Reeder T, Kimlinger T, et al. Flt-3 and c-kit Mutation Studies in a Spectrum of Chronic Myeloid Disorders Including Systemic Mast Cell Disease. *Leukemia Research*. 2003; 27(8): 739-742.

Park JY, Kim WY, Hwang TS, et al. BRAF and RAS Mutations in Follicular Variants of Papillary Thyroid Carcinoma. *Endocrine Pathology*. 2013; 24: 69-76.

Parker JS, Mullins M, Cheang MC, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. *J Clin Oncol*. 2009; 27: 1160-1167.

Patel J, Gönen M, Figueroa M, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. *The New England Journal of Medicine*. 2012; 366(12): 1079-1088.

Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. *Leukemia*. 2012; 26: 101-105.

Pfeifer H, Wassmann B, Pavlova A, et al. Kinase Domain Mutations of BCR-ABL frequently Precede Imatinib-Based Therapy and Give Rise to Relapse in Patients with De Novo Philadelphia-positive Acute Lymphoblastic Leukemia (Ph ALL). *Blood*. 2007; 110 (2): 727-734.

Pijnenborg JMA, van de Broek L, de Veen GCD, et al. TP53 overexpression in recurrent endometrial carcinoma. *Gynecologic Oncology*. 2006; 100: 397-404.

Plamadeala V, Huang S, McCreary SM, et al. Analytical performance of a formalin-fixed paraffinembedded tissue-based 634-probe prognostic assay for predicting outcome of patients with stage II colon cancer. *Appl Immunohistochem Mol Morphol*. 2014; 22(4):308-316.

Ponce C, de Lourdes F Chauffaille M, Ihara S, Silva M. MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis. *Leukemia Research*. 2012; 36: 93-97.

Popoveniuc G, Jonklaas J. Thyroid nodules. *Medical Clinics North America*. 2012; 96:329-34.

Postow MA, Carvajal RD. Therapeutic implications of KIT in melanoma. *Cancer J*. 2012; 18(2): 137-41.

Puccetti E, Beissert T, Güller S, et al. Leukemia-associated Translocation Products Able to Activate RAS Modify PML and Render Cells Sensitive to Arsenic-Induced Apoptosis. *Oncogene*. 2003; 22: 6900-6907.

QUASAR Collaborative Group: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. *Lancet*. 2007; 370:2020-2029.

Rampurwala M, Rocque G, Burkard, M. Update on Adjuvant Chemotherapy for Early Breast Cancer. *Breast Cancer: Basic and Clinical Research*. 2014; 8: 125-133.

Ratner ES, Keane FK, Lindner R, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. *Oncogene*. 2012; 31: 4559-4566.

Ravandi F, O'Brien S, Jones D, et al. T-Cell Prolymphocytic Leukemia: A Single-Institution Experience. *Clinical Lymphoma & Myeloma*. 2005; 6(3): 234-239.

Ravdin P, Siminoff L, Davis G, et al. Computer Program to assist in making decisions about adjuvant therapy for women with early breast cancer. *Journal of Clinical Oncology*. 2001; 19(4): 980-991.

Reeve T, Thompson NW. Complications of thyroid surgery: how to avoid them, how to manage them, and observations on their possible effect on the whole patient. *World Journal of Surgery*. 2000; 24: 971-5.

Ricci C, Fermo E, Corti S, et al. RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant. *Clinical Cancer Research*. 2010; 16(8): 2246-2256.

Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular Characterization of the Idiopathic Hypereosinophilic Syndrome (HES) in 35 French Patients with Normal conventional Cytogenetics. *Leukemia*. 2005; 19: 792-798.

Roh MH, Yassin Y, Miron A, et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. *Modern Pathology*. 2010; 23: 1316-1324.

Rosatto L, Avenia N, Bernante P, et al. Complications of Thyroid Surgery: Analysis of a Multicentric Study on 14,934 Patients Operated on in Italy over 5 Years. *World Journal of Surgery*. 2004; 28(3):271-6.

Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs Accurately Identify Cancer Tissue Origin. *Nature Biotechnology*. 2008; 26: 462-469.

Rossing M, Borup R, Henao R, et al. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. *Journal of Molecular Endocrinology*. 2012; 48, 11-23.

Roupret M, Catto J, Coulet F, et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. *J Med Genet*. 2004; 41: e91.

Russo A, Sala P, Alberici P, et al. Prognostic Relevance of MLH1 and MSH2 Mutations in Hereditary Non-Polyposis Colorectal Cancer Patients. *Tumori*. 2009; 95(6): 731-738.

Sabha N, Knobbe C, Maganti M, et al. Analysis of IDH Mutation, 1p/19q Deletion, and PTEN Loss Delineates Prognosis in Clinical Low-Grade Diffuse Gliomas. *Neuro-Oncology*. 2014; 16(7): 1-10.

Sacher, R A. Gene expression profiling advances in multiple myeloma. *HemOnc today*. 2010; 11 (23).

Santarpia L, Myers JN, Sherman SI, et al. Genetic Alterations in the Ras/Raf/Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signaling Pathways in the Follicular Variant of Papillary Thyroid Carcinoma. *Cancer*. 2010; 116: 2974-83.

Santos I, Franzon C, Koga A. Laboratory Diagnosis of Chronic Myelomonocytic Leukemia and Progression to Acute Leukemia in Association with Chronic Lymphocytic Leukemia: Morphological Features and Immunophenotypic Profile. *Rev Bras Hematol Hemoter*. 2012; 34(3): 242-244.

Sargent R, Jones D, Abruzzo L, et al. Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia. *Journal of Molecular Diagnostics*. 2009; 77(1): 25-34.

Schnittger S, Bacher U, Haferlach C, et al. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. *Leukemia*. 2011; 25: 615-621.

Schnittger S, Eder C, Jeromin S, et al. ASXL1 Exon 12 Mutations are Frequent in AML with Intermediate Risk Karyotype and are Independently Associated with an Adverse Outcome. *Leukemia*. 2013; 27(1): 82-91.

Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. *J Clin Oncol*. 2002; 20(19):3999-4005.

Schröder J, Kolkenbrock S, Tins J, et al. Analysis of Thrombopoietin Receptor (C-MPL) mRNA Expression in De Novo Acute Myeloid Leukemia. *Leukemia Research*. 2000; 24(5): 401-409.

Schwarz JK, Payton JE, Rashmi R, et al. Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer. *Clin Cancer Res*. 2012; 18: 1464-1471.

Senkus E, Kyriakides S, Ohno S, et al. Primary Breast Cancer: ESMO Clinical Practice Guidelines. *Annals of Oncology*. 2015; 26(5): 8-30. doi:10.1093/annonc/mdv298

Sestak I, Cuzick J. Markers for the identification of late breast cancer recurrence. *Breast Cancer Research*. 2015; 17(10): 1-8. DOI 10.1186/s13058-015-0516-0

Sestak I, Cuzick J, Dowsett M, et al. Predication of Late Distant Recurrence After 5 years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. *J Clin Oncol*. 2014; 33: 916-922.

Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination randomized trials using the PAM50 risk of recurrence score. *J Natl Cancer Inst*. 2013; 105: 1504-11.

Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. *American Society of Clinical Oncology*. 2015; 33(8): 916-925.

Sestak I, Dowsett M, Zabaglo L, et al. Factors Predicting Late Recurrence for Estrogen Receptor-Positive Breast Cancer. *J Natl Cancer Inst*. 2013 (Advance Access published September 12, 2013).

Shaughnessy Jr JD, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood*. 2007; 109: 2276-2284. Epub 2006 Nov 14.

Shaughnessy, JD et al. TP 53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. *British Journal of Haematology*. 2009; 147: 347-351.

Sheu S-Y, Grabelus F, Schwertheim S, et al. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. *British Journal of Cancer*. 2010; 102: 376-382.

Shih L-Y, Huang C-F, Lin T-L, et al. Heterogeneous Patterns of CEBPa Mutation Status in the Progression of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia to Acute Myelogenous Leukemia. *Clin Cancer Res*. 2005; 11: 1821-1826.

Siemiatkowska A, Bieniaszewska M, Hellmann A, Limon J. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. *Leukemia Research*. 2010; 34: 387-389.

Siitonen T, Savolainen LR, Koistinen P. Expression of the C-Kit Proto-Oncogene in Myeloproliferative Disorders and Myelodysplastic Syndromes. *Leukemia*. 1994; 8(4): 631-637.

Sikkema-Raddatz B, Johansson LF, de Boer EN, et al. Targeted Next-Generation Sequencing can Replace Sanger Sequencing in Clinical Diagnostics. *Human Mutations*. 2013; 34: 1035-1042.

Simon R, Paik S, Hayes D. Use of Archived specimens in evaluation or prognostic and predictive biomarkers. *Commentaries JNCI*. 2009; 101(21): 1446-1452.

Simon R. Moving from correlative science to predictive oncology. *EPMA Journal*. 2010; 1: 377-387.

Simon R. Lost in Translation Problems and Pitfalls in Translating Laboratory Observations to Clinical Utility. *Eur J Cancer*. 2008; 44(18): 2707-2713.

Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial. *Journal of Clinical Oncology*. 2012; 30 (36): 4524-4532.

Smith DL, Lamy A, Beaudenon-Huibregtse S, et al. A Multiplex Technology Platform for the Rapid Analysis of Clinically Actionable Genetic Alterations and Validation for BRAF p.V600E Detection in 1549 Cytologic and Histologic Specimens. *Archives of Pathology Laboratory Medicine*. 2014; 138: 371-378.

Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2V617F mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. *Leukemia Research*. 2010; 34: 821-823.

Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit Point Mutation Asp-816 Val in Microdissected Pooled Single Mast Cells and Leukemic Cells in a Patient with Systemic Mastocytosis and Concomitant Chronic Myelomonocytic Leukemia. *Leukemia Research*. 2002; 26(11): 979-984.

Sorensen SV, Goh JW, Pan F, et al. Incidence-based cost-of-illness model for metastatic breast cancer in the United States. *International Journal of Technology Assessment in Health Care*. 2012; 28(1): 12-21.

Spector Y, Fridman E, Rosenwald S, et al. Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. *Molecular Oncology*. 2013; 7:732-738.

Starczynowski DT, Vercauteren S, Telenius A, et.al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndrome reveals cryptic copy number alterations and predicts overall and leukemia-free survival. *Blood*. 2008; 112(8): 3412-3424. doi: 10.1182/blood-2007-11-122028

Stinchcombe TE, Roder J, Peterman AH, et al. A Retrospective Analysis Of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non-Small-Cell Lung Cancer. *J Thorac Oncol*. 2013; 8(4): 443-451.

Stokowy T, Wojtas B, Krajewska J, et.al. A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. *Molecular Cell Endocrinology*. 2015; 399: 43-49.

Stoll SJ, Pitt SC, Liu J, et al. Thyroid Hormone Replacement after Thyroid Lobectomy. *Surgery*. 2009; 146(4): 554-560.

Strimbu K, Tavel JA. What are Biomarkers? *Current opinion in HIV and AIDS*. 2010; 5(6): 463-466. doi:10.1097/COH.0b013e32833ed177

Surveillance, Epidemiology, and End Results (SEER). SEER Stat Fact Sheets: Colon and Rectum Cancer, 2015. Available at: <http://seer.cancer.gov/statfacts/html/colorect.html>

Surveillance, Epidemiology, and End Results (SEER) Program. Cancer statistics review 1975-2011. Section 26. thyroid. http://seer.cancer.gov/csr/1975_2011/browse_csr.php?sectionSEL=26&pageSEL=sect_26_table.22.html. Accessed on February 12, 2015

Swierniak M, Wojcicka A, Czetwertynska M, et al. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*. 2013; 98: E1401-1409.

Takahashi K, Jabbour E, Wang X, et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. *Leukemia*. 2013; 27: 2081-2083.

Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. *Annals of Internal Medicine*. 1997; 126(3): 226-31.

Tanaka S, Miyagi S, Sashida G, et al. Ezh2 Augments Leukemogenicity by Reinforcing Differentiation Blockage in Acute Myeloid Leukemia. *Blood*. 2012; 120 (5): 1107-1117.

Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin

(<http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?&MEDCACId=67&bc=AAAIAAAAAAAAAAAAA&TAId=90&>)

Tetzlaff MT, Liu A, Xu X, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. *Endocrine Pathology*. 2007; 18: 163-173.

The Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. *Cell*. 2014; 159: 676-690.

Tournigand C, Andre T, Bonnetain F, et al: Adjuvant therapy with fluorouracil and oxaliplatin in stage II and

elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. *J Clin Oncol*. 2012; 30(27): 3353-3360.

Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis. *Medicine*. 2012; 91(5): 274-286.

Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: The Whickham survey. *Clinical Endocrinology (Oxford)*. 1977; 7: 481-493.

Uegaki K, Kanamori Y, Kigawa J, et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. *Oncology Reports*. 2005; 14: 389-392.

Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors. *Obstet Gynecol*. 2011; 117(6): 1289-97.

Updated Clinical Utility Summary, dated 11/03/14 (Note: Original [or primary] study data is not presented in this summary, but just otherwise published results.)

Vaiman M, Nagibin A, Hagag P, et al. Hypothyroidism following partial thyroidectomy. *Otolaryngology: Head & Neck Surgery*. 2008; 138(1): 98-100.

van den Bent M, Dubbink H, Yannick M, et al. IDH1 And IDH2 Mutations are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. *Clin Cancer Res*. 2010; 16(5): 1597-1604.

van den Bent M, Gravendeel L, Gorlia T, et al. A Hypermethylated Phenotype is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. *Clin Cancer Res*. 2011; 17(22): 7148-7155.

Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. *Annals of Internal Medicine*. 1968; 69: 537-540.

Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic Strategies for Unknown Primary Cancer. *Cancer*. 2004; 100: 1776-85.

Varella-Garcia M, Brizard F, Roche J, et al. Aml1/ETO and Pml/RARA Rearrangements in a Case of AML-M2 Acute Myeloblastic Leukemia with t(15;17). *Leukemia and Lymphoma*. 1999; 33: 403-406.

Verbruggen MB, Sieben NLG, Roemen GMJM, et al. v-Raf Murine Sarcoma Viral Oncogene Mutation Status in Serous Borderline Ovarian Tumors and the Effect on Clinical Behavior. *Int J Gynecol Cancer*. 2009; 19: 1560-1563.

Verstovsek S. Advanced Systemic Mastocytosis: the Impact of KIT Mutations in Diagnosis, Treatment and Progression. *European Journal of Haematology*. 2013; 90(2): 89-98.

Volante M, Rapa I, Gandhi M, et al. RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact. *J Clin Endocrinol Metab*. 2009; 94(12): 4735-4741.

Wallden B, Storhoff J, Nielsen T, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. *BMC Medical Genomics*. 2015; 8: 54. doi:10.1186/s12920-015-0129-6.

Walter M, Payton J, Ries R, et al. Acquired Copy Number Alterations in Adult Acute Myeloid Leukemia Genomes. *PNAS*. 2009; 106 (31): 12950-12955.

Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. *Leukemia*. 2011; 25: 1153-1158.

Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. *Thyroid*. 2011; 21:243-251.

Wang X, Dai H, Wang Q, et al. EZH2 Mutations are Related to Low Blast Percentage in Bone Marrow and -7/del(7q) in De Novo Acute Myeloid Leukemia. *PLOS ONE*. 2013; 8 (4): 1-6.

Ware Miller R, Smith A, DeSimone CP, et al. Performance of the American College of Obstetricians and

- Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay. *Obstet Gynecol.* 2011; 117(6): 1298-306.
- Watanabe Y, Ueda H, Etoh T, et al. A Change in Promoter Methylation of hMLH1 is a Cause of Acquired Resistance to Platinum-based Chemotherapy in Epithelial Ovarian Cancer. *Anticancer Research.* 2007; 27: 1449-1452.
- Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. *Nature Reviews: Cancer.* 2013; 13: 184-99.
- Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biological significance of TP53 loss and the identification of potential novel transcriptional targets of TP 53 in multiple myeloma. *Blood.* 2008; 112(10): 4235-46.
- Yamada Y, Cancelas J. FIP1L1/PDGFRa-Associated Systemic Mastocytosis. *Int Arch Allergy Immunol.* 2010; 152(suppl 1): 101-104.
- Yang J, Schnadig V, Logrono R, et al. Fine-needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations. *Cancer (Cancer Cytopathology).* 2007; 111(5): 306-15.
- Yang Y, Shao N, Luo G, et al. Mutations of PTEN Gene in Gliomas Correlate to Tumor Differentiation and Short-Term Survival Rate. *Anticancer Research.* 2010; 30(3): 981-986.
- Yassa L, Cibas ES, Benson CB, et al. Long-term Assessment of a Multidisciplinary Approach to Thyroid Nodule Diagnostic Evaluation. *Cancer (Cancer Cytopathology).* 2007; 111: 508-16.
- Yip L, Farris C, Kabaker AS, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. *Journal of Clinical Endocrinology and Metabolism.* 2012; 97(6): 1905-12.
- Yip L. Molecular Markers for Thyroid Cancer Diagnosis, Prognosis, and Targeted Therapy. *Journal of Surgical Oncology.* 2015; 111: 43-50.
- Yip L, Wharry LI, Armstrong MJ, et al. A Clinical Algorithm for Fine-Needle Aspiration Molecular Testing Effectively Guides the Appropriate Extent of Initial Thyroidectomy. *Annals of Surgery.* 2014; 260: 163-168.
- Yoon S-Y, Li C-Y, Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. *Eur J Haematol.* 2000; 65: 170-174.
- Yuan ZM, Yang ZL, Zheng Q. Deregulation of microRNA expression in thyroid tumors. *Journal of Zhejiang University Sciences B.* 2014; 15: 212-224.
- Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-Cell Repertoire of the bone Marrow in Immune-Mediated Aplastic Anemia: Evidence for the Involvement of Antigen-Driven T-Cell Response in Cyclosporine-Dependent Aplastic Anemia. *Blood.* 1999; 93 (9): 3008-3016.
- Zenz T, Eichhorst B, Busch R, et al. TP53 Mutation and Survival in Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology.* 2010; 28 (29): 4473-4479.
- Zhan F, Barlogie B, Mulligan G, et al. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethazsone. *Blood.* 2008; 111: 968-969.
- Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. *Blood.* 2006; 108: 2020-2028.
- Zhang GN, Liu H, Huang JM, et al. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. *Gynecologic Oncology.* 2014; 132(3): 752-757.
- Zhang HY, Zhang PN, Sun H. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. *European Journal of Obstetrics & Gynecology and Reproductive Biology.* 2009; 146: 81-86.
- Zhou K, Jiang L, Shang Z, et al. Potential Application of *IDH1* and *IDH2* Mutations as Prognostic Indicators in Non-Promyelocytic Acute Myeloid Leukemia: a Meta-Analysis. *Leukemia & Lymphoma.* 2012; 53: 2423-2429.
- Zhou Y, Barlogie B, Shaughnessy Jr JD. The molecular characterization and clinical management of multiple myeloma in the post genome era. Spotlight Review. *Leukemia.* 2009; 23: 1941-1956.

Zhong Y, Chen B, Feng J, et al. The Associations of Janus Kinase-2 (JAK2) A830G Polymorphism and the Treatment Outcomes in Patients with Acute Myeloid Leukemia. *Leukemia & Lymphoma*. 2010: 1115-1120.

http://www.accessdata.fda.gov/cdrh_docs/reviews/K081754.pdf

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p030052>

<http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/American+Society+of+Clinical+Oncology+Provisional+Clinical+Opinion%3A+Epidermal+Growth+Factor+Receptor+%28EGFR%29+Mutation+Testing+for+Patients+with+Advanced+Non-Small+Cell+Lung+Cancer+Considering+First-Line+EGFR+Tyrosine-Kinase+Inhibitor+%28TKI%29+Therapy>

<http://www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=67&bc=AAAIAAAAAAAAAAAA%3d%3d&> (Minutes from this May 1, 2013 MEDCAC to be posted between July 1-September 1, 2013)

<http://www.egapreviews.org/recommendations/colorectal.htm>

<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294907.htm>

<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm>

<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310899.htm>

<http://www.gen-probe.com/products-services/progensa-pca3>

<http://www.medscape.com/viewarticle/775368>

<http://www.nationalcmlsociety.org/living-cml/monitoring-tests>

<http://www.nccn.org/professionals/biomarkers/default.asp>

http://www.novitas-solutions.com/webcenter/faces/oracle/webcenter/page/scopedMD/sad78b265_6797_4ed0_a02f_81627913bc78/Page41.jspx?wc.contextURL=%2Fspaces%2FMedicareJH&wc.originURL=%2Fspaces%2FMedicareJH%2Fpage%2Fpagebyid&contentId=00024692&_afLoop=2523822121000#%40%3F_afLoop%3D2523822121000%26wc.originURL%3D%252Fspaces%252FMedicareJH%252Fpage%252Fpagebyid%26contentId%3D00024692%26wc.contextURL%3D%252Fspaces%252FMedicareJH%26_adf.ctrl-state%3Dxegaeqb38_128

There were extensive in-person consultations with both CAC representatives and nationally-recognized experts in order to assist with the above medical necessity language and procedure-to-diagnosis code pairings.

Other Contractor Policies

Noridian Local Coverage Determination (LCD), DL36380 - MoIDX: Breast Cancer Assay: Prosigna

Contractor Medical Directors

Bibliography

N/A

[Back to Top](#)

Revision History Information

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
01/01/2018	R21		

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
		<p>LCD revised and published on 01/25/2018 effective for dates of service on and after 01/01/2018 to reflect the annual CPT/HCPCS code updates. For the following CPT/HCPCS codes either the short description and/or the long description was changed: 81400, 81401, 81403, 81404, 81405, 81406. Depending on which description is used in this LCD there may not be any change in how the code displays in the document. The following CPT/HCPCS codes have been added to CPT/HCPCS Code Group 1: 81120, 81121, 81175, 81176, 81334, 81520. The following CPT/HCPCS code has been deleted from CPT code group 1: 0008M. To clarify coverage for the new CPT/HCPCS code additions, ICD-10 Group Code Paragraphs have been updated as follows: Group 4: IDH1 (81120) and IDH2 (81121); Group 10: RUNX1 (81334); Group 11: ASXL1 (81175, 81176), IDH1 (81120), IDH2 (81121) and RUNX1 (81334); Group 15: ASXL1 (81175, 81176); Group 22: ASXL1 (81175, 81176), IDH1 (81120) and IDH2 (81121); and Group 24: 81520 has been added and 0008M has been deleted.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.</p>	<ul style="list-style-type: none"> Revisions Due To CPT/HCPCS Code Changes
11/09/2017	R20	<p>LCD revised and published on 11/09/2017 effective for dates of service on and after 08/01/2017 to add the following new CPT/HCPCS codes for Proprietary Laboratory Analyses (PLA) to Group 2 CPT/HCPCS Codes as non-covered: 0009U, 0013U, 0014U, 0016U, and 0017U. LCD revised with effective dates of service on and after 10/02/2017 to reflect the 4Q17 CPT/HCPCS code updates. For the following CPT/HCPCS code(s) either the short description and/or the long description was changed: 81405 and 0002U. Depending on which description is used in this LCD, there may not be any change in how the code displays in the document.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.</p>	<ul style="list-style-type: none"> Revisions Due To CPT/HCPCS Code Changes
10/01/2017	R19	<p>LCD revised and published on 10/05/2017 effective for dates of service on and after 10/01/2017 to reflect the ICD-10 Annual Code Updates. The following ICD-10 code has been deleted from Group 20 codes: C96.2. The following ICD-10 codes have been added to Group 20 codes: C96.20, C96.22, C96.29.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.</p>	<ul style="list-style-type: none"> Revisions Due To ICD-10-CM Code Changes
08/10/2017	R18	<p>LCD revised and published on 08/10/2017 effective for dates of service on and after 05/01/2017 to add the following CPT code as non-covered to Group 2 Codes: 0005U.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</p>	<ul style="list-style-type: none"> Revisions Due To CPT/HCPCS Code Changes
02/01/2017	R17		<ul style="list-style-type: none"> Reconsideration Request

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
		LCD revised and published on 07/13/2017 to add references received with a reconsideration request for CxBladder coverage. After review of the submitted literature it has been determined that non-coverage of CxBladder will remain. No substantial changes are being made to the LCD at this time.	
		At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	
02/01/2017	R16	LCD revised and published on 05/11/2017 effective for dates of service on and after 02/01/2017 to add the following CPT codes as non-covered to Group 2 Codes: 0002U and 0003U. An explanation of non-coverage for these codes has been added to the Limitation section of the policy.	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code Changes
01/01/2017	R15	LCD revised and published on 01/12/2017 effective for dates of service on and after 01/01/2017 to reflect the annual CPT/HCPCS code updates. For the following CPT/HCPCS codes either the short description and/or the long description was changed. Depending on which description is used in this LCD, there may not be any change in how the code displays in the document: 81402 and 81407. The following CPT/HCPCS code 81327 has been added to group 1 CPT codes and Group 1 Paragraph for ICD-10 codes of the LCD.	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code Changes
12/01/2016	R14	LCD posted for notice on 10/13/2016. LCD becomes effective for dates of service and after 12/01/2016.	<ul style="list-style-type: none"> • Automated Edits to Enforce Reasonable & Necessary Requirements
		05/19/2016 DL35396 Draft LCD posted for comment.	
10/01/2016	R13	LCD revised and published on 09/29/2016 effective for dates of service on and after 10/01/2016 to reflect the ICD-10 Annual Code Updates. The following ICD-10 codes have been added to the list of Group 8 diagnosis codes: N42.31, N42.32 and N42.39. The following ICD-10 codes have been added to Group 9 diagnosis codes: C49.A0, C49.A1, C49.A2, C49.A3, C49.A4, C49.A5 and C49.A9. The following Group 8 ICD-10 codes have undergone a descriptor change: N40.0 and N40.1.	<ul style="list-style-type: none"> • Revisions Due To ICD-10-CM Code Changes
01/22/2016	R12	LCD revised and published on 05/12/2016 to correct source for Starczynowski.	<ul style="list-style-type: none"> • Typographical Error
01/22/2016	R11	LCD revised and published on 04/14/2016, effective for dates of service 01/22/2016, to add limited coverage for Prosigna upon additional reconsideration request. A new Group for CPT/HCPCS code 0008M was created for the following ICD-10 codes for 0008M: C50.011, C50.012, C50.019, C50.111, C50.112, C50.119, C50.211, C50.212, C50.219, C50.311, C50.312, C50.319, C50.411, C50.412, C50.419, C50.511, C50.512, C50.519, C50.611, C50.612, C50.619, C50.811, C50.812, C50.819, C50.911, C50.912, C50.919. Submitted sources have been added to the LCD. Please note: The content of this LCD version remains the same as the prior version (R10) except that additional codes have been added to the Revision History for this version to accurately reflect all the code additions.	<ul style="list-style-type: none"> • Reconsideration Request
01/22/2016	R10	LCD revised and published on 04/14/2016, effective for dates of service on and after 01/22/2016, to add limited coverage for Prosigna upon additional reconsideration request. A new Group for CPT/HCPCS code 0008M was created for the following ICD-10 codes for 0008M: C50.011, C50.012, C50.111, C50.112, C50.211, C50.212, C50.311, C50.312, C50.411, C50.412, C50.511, C50.512, C50.611, C50.612, C50.811, C50.812, C50.911, C50.912. Submitted sources have been added to the LCD.	<ul style="list-style-type: none"> • Reconsideration Request

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
01/01/2016	R9	LCD revised and published on 02/11/2016, effective for dates of service 12/14/2015 and after, to add coverage for ThyraMIR services reported with CPT code 81479. The following ICD-10 codes have been added to Group 5 for ThyraMIR: E01.0, E01.2, E04.0, E04.8, E04.9. LCD revised and published on 01/28/2016 to reflect the annual CPT/HCPCS code updates. For the following CPT/HCPCS codes, either the short description or the long description was changed. Depending on which description is used in this LCD, there may not be any change in how the code displays in the document: 81210, 81275, 81402, 81435, 81436, 81445, 81450. The following code has been added to CPT group 2 as NON-COVERED; 81595 as the service represented by this code is currently non-covered per the LCD under the non-conventional methods of NGS limitation. CPT code 81170 has been added to groups 10 and 16 to replace 81403 for reporting ABL1. CPT code 81218 has been added to groups 11 and 23 to replace 81403 for CEBPA. CPT code 81272 has been added to groups 3 and 9 to replace 81404 for KIT. CPT 81273 has been added to groups 11, 16, 19, 21, and 23 to replace 81402 for KIT. CPT 81276 has been added to groups 1, 2, 5, 6, 11, 16, and 23. CPT code 81311 has been added to groups 1, 3, 5, 11, 16, and 23 to replace 81404 associated with NRAS. CPT code 81314 has been added to group 9 to replace 81404 associated with PDGFRA. CPT code 81538 has been added for VeriStrat® testing to group 2 diagnosis.	<ul style="list-style-type: none"> Reconsideration Request Revisions Due To CPT/HCPCS Code Changes
01/01/2016	R8	LCD revised and published on 11/13/2015 to add ICD-10 diagnosis codes with higher specificity to Group 5 effective for dates of service on and after 10/01/2015. Diagnosis codes added to Group 5: D44.2, D44.9, E01.1. Sources from reconsideration requests have been reviewed and added to the LCD sources. No substantial changes have been made based on the reconsiderations.	<ul style="list-style-type: none"> Reconsideration Request Other (Clarification)
10/01/2015	R7	LCD revised and published on 10/08/2015 to reflect that OVA1 should be reported with CPT 81503 rather than 84999 effective for dates of service on and after 10/01/2015.	<ul style="list-style-type: none"> Revisions Due To CPT/HCPCS Code Changes
10/01/2015	R6	LCD revised and published on 08/13/2015 to add multiple sources submitted with several reconsideration requests regarding Prosigna, molecular kidney cancer testing and bladder cancer testing. All literature was reviewed. No changes to the policy were made based on these reconsideration requests.	<ul style="list-style-type: none"> Reconsideration Request
10/01/2015	R5	LCD revised and published on 01/23/2015 to reflect the annual CPT/HCPCS code updates For the following CPT/HCPCS code(s) either the short description and/or the long description was changed. Depending on which description is used in this LCD, there may not be any change in how the code displays in the document: 81245; 81402; 81403; 81404; 81405. The following codes have been added to CPT group 2 as NON-COVERED; 81445, 81450 and 81455. The following codes have been added to the LCD but will not have any diagnosis to procedure code editing at this time; 81246; 81435; and 81436. CPT code 81313 has been added to group 8 to replace 81479 for reporting PROGENSA® PCA3 Assay. Original and subsequent decisions to non-cover Prosigna are reaffirmed upon additional reconsideration request. Submitted sources have been added to the LCD.	<ul style="list-style-type: none"> Revisions Due To CPT/HCPCS Code Changes Reconsideration Request
10/01/2015	R4	LCD revised and published on 10/09/2014, effective for dates of service on or after 10/01/2015. Non-coverage for Prosigna reaffirmed upon reconsideration request. LCD revised to add ICD-10-CM codes under group 5 for indeterminate malignancy, as well as presumed or documented malignancy of the thyroid gland per a reconsideration request. LCD also revised to add limited coverage for MyPRS multiple myeloma testing.	<ul style="list-style-type: none"> Reconsideration Request
10/01/2015	R3		<ul style="list-style-type: none"> Typographical Error
10/01/2015	R2		

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
10/01/2015	R1	<p>10/01/2014 LCD revised and published on 08/14/2014 to provide clarifications to the statement regarding next generation sequencing methods in the limitations section and to the cancer of unknown primary testing area. Reference to Local Coverage Article A52986 was inserted into LCD.</p> <p>10/01/2014 LCD revised and published on 08/14/2014 to provide clarifications to the statement regarding next generation sequencing methods in the limitations section and to the cancer of unknown primary testing area. Reference to Local Coverag Article A52986 was inserted into LCD.</p>	<ul style="list-style-type: none"> Other (Clarification)

[Back to Top](#)

[Associated Documents](#)

Attachments N/A

Related Local Coverage Documents Article(s) [A52986 - Biomarkers for Oncology](#) LCD(s) [DL35396](#) - (MCD Archive Site)

Related National Coverage Documents NCD(s) [210.3 - Colorectal Cancer Screening Tests](#)

Public Version(s) Updated on 01/19/2018 with effective dates 01/01/2018 - N/A [Updated on 11/03/2017 with effective dates 11/09/2017 - 12/31/2017](#) [Updated on 09/29/2017 with effective dates 10/01/2017 - 11/08/2017](#) [Updated on 08/04/2017 with effective dates 08/10/2017 - 09/30/2017](#) [Updated on 07/06/2017 with effective dates 02/01/2017 - 08/09/2017](#) [Updated on 05/05/2017 with effective dates 02/01/2017 - N/A](#) [Updated on 01/06/2017 with effective dates 01/01/2017 - 01/31/2017](#) Some older versions have been archived. Please visit the [MCD Archive Site](#) to retrieve them. [Back to Top](#)

[Keywords](#)

N/A Read the [LCD Disclaimer](#) [Back to Top](#)